| 股票 | 标签 | 申万二级 | PE | 前瞻PE | PEG | PB | 股息率 | 分红率 | 毛利率 | 固定资产 | 债/EBITDA | FCF/市值 | 营收3年 | 去年 | YTD | 近一年 | 回撤 | 波动 | 市值亿 ▴ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 博迅生物 920504 | 中性 | 医疗器械 | 45.4 | — | — | 4.03 | 1.1% | 59% | 40% | 19% | 0.8 | 1.1% | -6% | +37% | -21% | — | — | — | 8 |
| 辰光医疗 920300 | 亏损或困境 | 医疗器械 | — | — | — | 5.63 | — | — | 40% | 31% | — | -0.4% | -22% | +32% | -34% | — | — | — | 9 |
| 生物谷 920266 | 亏损或困境 | 中药Ⅱ | — | — | — | 1.05 | — | — | 80% | 40% | 0.6 | -6.1% | -10% | -3% | -18% | — | — | — | 9 |
| 欧康医药 920230 | 中性 | 化学制药 | 79.2 | — | — | 2.65 | 1.4% | 91% | 21% | 48% | 0.5 | -1.4% | +7% | +13% | -9% | — | — | — | 11 |
| 峆一药业 920478 | 中性 | 化学制药 | 157.0 | — | — | 2.24 | 1.0% | 32% | 37% | 46% | 2.5 | -8.1% | +4% | +57% | -22% | — | — | — | 11 |
| 鹿得医疗 920278 | 中性 | 医疗器械 | 88.0 | — | — | 2.97 | 1.5% | 63% | 25% | 30% | 1.9 | -2.6% | -4% | +27% | -26% | — | — | — | 11 |
| 中科美菱 920992 | 纯久期 | 医疗器械 | 64.6 | 52.0 | 4.00 | 1.84 | 0.8% | 46% | 36% | 12% | 0.2 | 2.4% | -9% | +28% | -31% | — | — | — | 12 |
| 锦好医疗 920925 | 中性 | 医疗器械 | 715.2 | — | — | 3.29 | 0.4% | 50% | 46% | 25% | 0.7 | 0.2% | +16% | +174% | -62% | — | — | — | 12 |
| *ST益通 300430 | 亏损或困境 | 医疗器械 | — | — | — | 0.96 | — | 14% | 42% | 25% | — | -15.8% | -22% | +26% | -76% | -80% | -86% | 67% | 13 |
| 大唐药业 920433 | 亏损或困境 | 中药Ⅱ | — | — | — | 3.41 | — | 208% | 71% | 69% | — | -0.9% | -5% | -3% | -16% | — | — | — | 13 |
| *ST康乐 920575 | 亏损或困境 | 生物制品 | — | — | — | — | — | — | 96% | 77% | — | -4.8% | -9% | -50% | -43% | — | — | — | 13 |
| 睿昂基因 688217 | 亏损或困境 | 医疗器械 | — | — | — | 1.64 | 0.7% | 129% | 73% | 38% | 0.8 | 2.8% | -25% | +44% | -7% | -21% | -45% | 43% | 14 |
| 爱得科技 920180 | 中性 | 医疗器械 | 21.6 | 16.8 | 1.29 | 1.83 | 2.5% | 34% | 59% | 18% | — | 0.1% | +2% | — | — | — | — | — | 14 |
| 梓橦宫 920566 | 轻资产现金牛 | 化学制药 | 16.6 | — | — | 1.67 | 2.0% | 34% | 80% | 15% | 0.1 | 4.3% | -1% | +23% | -10% | — | — | — | 14 |
| 数字人 920670 | 亏损或困境 | 医疗服务 | 346.0 | — | — | 6.03 | 0.4% | 65% | 69% | 14% | 0.2 | 1.9% | +12% | +9% | -20% | — | — | — | 14 |
| 无锡晶海 920547 | 中性 | 生物制品 | 22.8 | 19.9 | 0.87 | 2.08 | 1.0% | 26% | 32% | 34% | 0.0 | 0.9% | +2% | +52% | -16% | — | — | — | 15 |
| 海昇药业 920656 | 中性 | 化学制药 | 17.9 | — | — | 2.17 | 2.6% | 38% | 52% | 28% | — | 3.6% | -6% | +41% | -9% | — | — | — | 15 |
| 海圣医疗 920166 | 中性 | 医疗器械 | 19.1 | — | — | 2.41 | — | — | 52% | 44% | 0.0 | 0.6% | +9% | — | — | — | — | — | 15 |
| 爱威科技 688067 | 中性 | 医疗器械 | 49.1 | — | — | 3.04 | 0.6% | 31% | 59% | 21% | 1.0 | 1.9% | +4% | +48% | -4% | -14% | -38% | 36% | 16 |
| 普昂医疗 920069 | 中性 | 医疗器械 | 17.9 | 15.8 | 0.53 | 2.22 | 1.5% | 24% | 48% | 0% | — | 2.6% | +16% | — | — | — | — | — | 18 |
| ST金花 600080 | 亏损或困境 | 中药Ⅱ | 178.0 | — | — | 1.14 | — | 14% | 76% | 32% | 2.3 | -2.0% | -2% | -3% | -36% | -39% | -52% | 37% | 18 |
| ST南新 688189 | 亏损或困境 | 化学制药 | — | — | — | 2.35 | — | — | 83% | 17% | — | -0.7% | -41% | +22% | -16% | -55% | -67% | 69% | 18 |
| ST天圣 002872 | 亏损或困境 | 化学制药 | — | — | — | 0.96 | — | — | 48% | 50% | 4.4 | 1.8% | -5% | +7% | +20% | +18% | -22% | 30% | 18 |
| 新赣江 920367 | 中性 | 化学制药 | 160.7 | — | — | 3.88 | 0.1% | 15% | 45% | 44% | 2.6 | -2.9% | -13% | +44% | +31% | — | — | — | 19 |
| 科莱瑞迪 920072 | 中性 | 医疗器械 | 27.4 | — | — | 2.54 | — | — | 63% | 31% | 0.0 | 2.5% | +11% | — | — | — | — | — | 19 |
| 安必平 688393 | 亏损或困境 | 医疗器械 | — | — | — | 1.67 | 0.5% | 39% | 68% | 18% | 0.4 | -0.1% | -12% | +38% | -14% | -38% | -53% | 46% | 19 |
| ST嘉应 002198 | 中性 | 中药Ⅱ | — | — | — | 2.69 | — | 74% | 65% | 26% | 0.6 | -6.5% | -16% | -4% | -47% | -45% | -65% | 46% | 19 |
| 仁度生物 688193 | 纯久期 | 医疗器械 | 108.8 | — | — | 2.17 | 2.3% | 269% | 78% | 7% | 0.1 | 0.7% | -19% | +37% | +1% | -12% | -33% | 41% | 19 |
| 港通医疗 301515 | 亏损或困境 | 医疗器械 | — | — | — | 1.59 | — | 96% | 27% | 7% | — | -2.2% | -2% | +12% | -4% | -18% | -40% | 44% | 19 |
| ST迪瑞 300396 | 亏损或困境 | 医疗器械 | — | — | — | 1.26 | — | 96% | 52% | 7% | — | -4.6% | -13% | -20% | -44% | -53% | -60% | 36% | 20 |
| 金迪克 688670 | 亏损或困境 | 生物制品 | — | — | — | 1.88 | — | — | 78% | 61% | — | -8.0% | -29% | +67% | -21% | -4% | -58% | 76% | 20 |
| 爱伦医疗 920050 | 现金流红利 | 医疗器械 | 18.4 | 17.2 | 0.75 | 1.88 | 3.4% | 54% | 23% | 51% | 2.0 | -5.2% | +20% | — | — | — | — | — | 20 |
| 天臣医疗 688013 | 现金流红利 | 医疗器械 | 39.4 | — | — | 4.03 | 5.2% | 253% | 58% | 32% | 2.2 | -1.6% | +12% | +209% | -48% | -44% | -66% | 46% | 20 |
| 黄山胶囊 002817 | 中性 | 化学制药 | 33.8 | — | — | 2.07 | 1.3% | 39% | 29% | 24% | — | 5.8% | +2% | +24% | -11% | -15% | -34% | 31% | 20 |
| 星昊医药 920017 | 现金流红利 | 化学制药 | 17.7 | — | — | 1.25 | 3.6% | 54% | 74% | 40% | 0.1 | 4.5% | +2% | +33% | -6% | — | — | — | 20 |
| 新天药业 002873 | 中性 | 中药Ⅱ | 250.1 | — | — | 1.61 | 0.3% | 42% | 77% | 34% | 8.1 | 2.8% | -12% | +6% | -15% | -37% | -44% | 34% | 21 |
| *ST海利 603718 | 亏损或困境 | 医疗器械 | — | — | — | 2.30 | — | 29% | 59% | 8% | 1.7 | 1.6% | -14% | -11% | -48% | -57% | -64% | 40% | 21 |
| 西点药业 301130 | 中性 | 化学制药 | 353.7 | — | — | 2.39 | 0.5% | 50% | 80% | 51% | 1.0 | -1.0% | -3% | +10% | -4% | -17% | -34% | 50% | 21 |
| 本立科技 301065 | 重资产陷阱 | 化学制药 | 26.4 | — | — | 1.50 | 1.5% | 32% | 17% | 37% | 0.0 | -3.8% | -6% | +15% | -7% | -18% | -32% | 30% | 21 |
| 光正眼科 002524 | 亏损或困境 | 医疗服务 | — | — | — | 18.60 | — | — | 35% | 12% | 5.6 | 5.0% | +5% | +13% | -2% | -12% | -40% | 41% | 21 |
| 阳普医疗 300030 | 亏损或困境 | 医疗器械 | 70.1 | — | — | 3.24 | — | — | 41% | 37% | 1.0 | 5.8% | -12% | +33% | -7% | -23% | -33% | 37% | 21 |
| 达嘉维康 301126 | 亏损或困境 | 医药商业 | — | — | — | 1.41 | 0.2% | 43% | 15% | 11% | 12.8 | -2.8% | +16% | +19% | -16% | -18% | -44% | 42% | 21 |
| 奥精医疗 688613 | 纯久期 | 医疗器械 | 251.0 | — | — | 1.51 | 0.2% | 30% | 83% | 11% | 1.0 | -1.5% | -3% | +13% | -22% | -24% | -54% | 51% | 22 |
| 莎普爱思 603168 | 亏损或困境 | 化学制药 | — | — | — | 1.60 | — | 30% | 56% | 42% | — | -5.0% | -6% | +10% | -20% | -27% | -46% | 37% | 22 |
| 皓宸医疗 002622 | 亏损或困境 | 医疗服务 | — | — | — | 8.43 | — | — | 47% | 11% | 5.9 | 3.8% | +12% | +8% | -12% | -36% | -54% | 41% | 22 |
| 恩威医药 301331 | 纯久期 | 中药Ⅱ | 74.5 | — | — | 2.16 | 4.8% | 65% | 51% | 18% | 2.4 | 2.3% | +9% | +16% | -16% | -44% | -47% | 42% | 22 |
| 广济药业 000952 | 亏损或困境 | 化学制药 | — | — | — | 3.70 | — | — | 27% | 51% | 77.7 | 2.8% | -8% | +14% | -8% | -6% | -51% | 48% | 22 |
| 古汉医药 000590 | 亏损或困境 | 中药Ⅱ | — | — | — | 4.16 | — | — | 51% | 36% | 6.4 | -3.0% | -1% | +58% | -17% | -24% | -40% | 35% | 22 |
| 汉商集团 600774 | 亏损或困境 | 化学制药 | — | — | — | 1.49 | — | — | 62% | 49% | 5.9 | 3.5% | -9% | +22% | -16% | -25% | -49% | 39% | 22 |
| 中哲精化 000953 | 重资产陷阱 | 化学制药 | 640.9 | — | — | 14.42 | — | — | 15% | 49% | — | 0.8% | +4% | +29% | -16% | -20% | -39% | 37% | 22 |
| 仟源医药 300254 | 亏损或困境 | 化学制药 | 77.8 | — | — | 4.98 | — | — | 68% | 17% | 3.2 | 5.6% | +2% | +16% | -14% | -28% | -50% | 47% | 22 |
| 新光药业 300519 | 中性 | 中药Ⅱ | 37.0 | — | — | 2.77 | 2.1% | 97% | 41% | 10% | — | 3.9% | -9% | +15% | -2% | -15% | -31% | 38% | 23 |
| 益盛药业 002566 | 纯久期 | 中药Ⅱ | 62.6 | — | — | 1.04 | 1.1% | 64% | 74% | 13% | 6.1 | 4.3% | -8% | +14% | -7% | -15% | -35% | 35% | 23 |
| 康为世纪 688426 | 亏损或困境 | 医疗器械 | — | — | — | 1.79 | — | — | 65% | 22% | — | -2.9% | -28% | -17% | -12% | -14% | -55% | 47% | 24 |
| 第一医药 600833 | 中性 | 医药商业 | 33.9 | — | — | 2.11 | 0.7% | 30% | 18% | 5% | 1.9 | 1.7% | -7% | -3% | -17% | -21% | -40% | 36% | 24 |
| 富士莱 301258 | 中性 | 化学制药 | 359.0 | — | — | 1.29 | 0.8% | 49% | 38% | 26% | 0.0 | -6.7% | -9% | +38% | -20% | -30% | -41% | 36% | 24 |
| ST葫芦娃 605199 | 亏损或困境 | 中药Ⅱ | — | — | — | 7.97 | — | 310% | 51% | 57% | — | 5.8% | -16% | -52% | -22% | -36% | -49% | 34% | 24 |
| 浙江震元 000705 | 重资产陷阱 | 医药商业 | — | — | — | 1.24 | — | 42% | 19% | 38% | 4.1 | -2.2% | -18% | +15% | -20% | -25% | -43% | 29% | 24 |
| 药易购 300937 | 亏损或困境 | 医药商业 | — | — | — | 2.97 | — | 47% | 8% | 7% | 8.1 | -0.3% | +4% | +37% | -26% | -16% | -55% | 58% | 24 |
| 优宁维 301166 | 亏损或困境 | 生物制品 | — | — | — | 1.27 | 2.1% | 146% | 20% | 12% | — | -5.4% | -3% | +6% | -2% | -14% | -29% | 38% | 25 |
| 健之佳 605266 | 现金流红利 | 医药商业 | 19.0 | — | — | 0.97 | 7.6% | 127% | 36% | 12% | 3.1 | 45.6% | +6% | -13% | -11% | -22% | -29% | 27% | 25 |
| 东亚药业 605177 | 亏损或困境 | 化学制药 | — | — | — | 1.58 | — | 30% | 27% | 59% | 27.9 | -1.0% | -7% | -10% | +23% | +5% | -40% | 43% | 25 |
| 三元基因 920344 | 中性 | 生物制品 | 189.8 | 134.2 | 1.74 | 4.04 | — | 29% | 80% | 58% | 7.3 | 2.2% | +19% | +32% | -11% | — | — | — | 25 |
| 科美诊断 688468 | 中性 | 医疗器械 | 72.2 | — | — | 1.78 | — | 36% | 75% | 24% | 2.6 | 2.9% | -11% | +9% | -14% | -28% | -37% | 27% | 25 |
| 华神科技 000790 | 亏损或困境 | 中药Ⅱ | — | — | — | 3.54 | — | 22% | 41% | 41% | — | 1.8% | -14% | -1% | +6% | -3% | -24% | 36% | 26 |
| 康拓医疗 688314 | 中性 | 医疗器械 | 30.1 | 21.5 | 1.02 | 3.44 | 1.6% | 34% | 81% | 25% | 0.8 | 2.4% | +14% | +16% | -4% | -20% | -48% | 52% | 26 |
| 赛托生物 300583 | 亏损或困境 | 化学制药 | 263.0 | — | — | 1.46 | 0.1% | 180% | 21% | 48% | 3.1 | 4.9% | -8% | -30% | -1% | -25% | -39% | 36% | 26 |
| 何氏眼科 301103 | 纯久期 | 医疗服务 | 105.7 | — | — | 1.36 | 0.9% | 119% | 40% | 13% | 1.0 | 4.4% | +5% | -2% | -16% | -30% | -38% | 30% | 26 |
| 易瑞生物 300942 | 亏损或困境 | 医疗器械 | — | 54.4 | 1.30 | 3.26 | 0.4% | 63% | 64% | 38% | 9.3 | -0.0% | -27% | +10% | -30% | -50% | -59% | 40% | 26 |
| 天目药业 600671 | 亏损或困境 | 中药Ⅱ | 194.8 | — | — | 34.92 | — | — | 31% | 38% | 3.7 | 1.0% | +25% | +97% | +26% | +10% | -29% | 45% | 27 |
| 西山科技 688576 | 亏损或困境 | 医疗器械 | — | 20.5 | 0.71 | 1.58 | 0.8% | 51% | 70% | 23% | — | -2.8% | +9% | +3% | -6% | -17% | -38% | 38% | 27 |
| 南华生物 000504 | 亏损或困境 | 医疗服务 | 69.8 | — | — | 9.84 | — | — | 67% | 18% | 3.2 | -4.8% | +28% | +7% | -10% | -17% | -32% | 40% | 27 |
| 溢多利 300381 | 亏损或困境 | 化学制药 | — | — | — | 1.06 | 0.9% | 158% | 44% | 50% | 0.3 | -5.3% | -11% | -6% | -14% | -28% | -30% | 35% | 27 |
| 正海生物 300653 | 中性 | 医疗器械 | 38.7 | — | — | 3.08 | 1.8% | 61% | 89% | 21% | — | 2.4% | -6% | -4% | -24% | -32% | -39% | 34% | 27 |
| 国发股份 600538 | 亏损或困境 | 医药商业 | — | — | — | 4.01 | — | — | 26% | 11% | — | -1.1% | -11% | +19% | -16% | -23% | -42% | 39% | 27 |
| 共同药业 300966 | 亏损或困境 | 化学制药 | — | 118.0 | 1.18 | 3.90 | 0.2% | 8% | 22% | 64% | 17.2 | -0.6% | +0% | +22% | +20% | +1% | -31% | 43% | 27 |
| 爱朋医疗 300753 | 亏损或困境 | 医疗器械 | — | 156.0 | 11.14 | 4.19 | — | 87% | 66% | 20% | 6.9 | 1.1% | +2% | +58% | -21% | -40% | -58% | 69% | 28 |
| 南卫股份 603880 | 重资产陷阱 | 医疗器械 | — | — | — | 17.53 | — | — | 9% | 50% | — | 1.1% | +3% | +43% | +55% | +44% | -34% | 49% | 28 |
| 尚荣医疗 002551 | 亏损或困境 | 医疗器械 | — | — | — | 1.14 | — | 30% | 17% | 13% | — | -0.0% | -6% | +19% | -9% | -28% | -41% | 32% | 28 |
| 透景生命 300642 | 纯久期 | 医疗器械 | 228.4 | 216.5 | 1.34 | 1.96 | 0.9% | 70% | 66% | 19% | 4.7 | 4.8% | -20% | +32% | -5% | -39% | -64% | 59% | 28 |
| 东星医疗 301290 | 亏损或困境 | 医疗器械 | — | 23.7 | 0.35 | 1.31 | 1.1% | 62% | 49% | 14% | 1.2 | 1.6% | -4% | +12% | +12% | +4% | -36% | 39% | 28 |
| 天益医疗 301097 | 亏损或困境 | 医疗器械 | — | — | — | 2.77 | 1.0% | 46% | 38% | 42% | 6.3 | -12.3% | +13% | +44% | -5% | +6% | -36% | 51% | 28 |
| 丹娜生物 920009 | 中性 | 医疗器械 | 30.6 | 23.4 | 1.30 | 4.12 | 1.0% | 25% | 84% | 9% | 0.0 | 2.1% | -6% | — | -31% | — | — | — | 29 |
| 同和药业 300636 | 中性 | 化学制药 | 73.2 | 32.5 | 1.55 | 1.21 | 0.6% | 16% | 32% | 55% | 2.6 | -1.4% | +5% | -5% | -9% | -19% | -32% | 30% | 29 |
| 麦澜德 688273 | 中性 | 医疗器械 | 38.0 | 25.3 | 1.69 | 2.15 | 2.7% | 78% | 71% | 28% | 0.4 | -0.1% | +5% | +90% | -32% | -36% | -54% | 62% | 29 |
| 拓新药业 301089 | 亏损或困境 | 化学制药 | — | — | — | 1.98 | — | 13% | 38% | 51% | — | -2.3% | -22% | -1% | -18% | -35% | -42% | 41% | 29 |
| 丰原药业 000153 | 中性 | 化学制药 | 30.6 | — | — | 1.34 | 1.6% | 31% | 26% | 35% | 5.1 | 1.7% | -1% | +4% | +1% | -10% | -28% | 30% | 29 |
| 洁特生物 688026 | 中性 | 医疗器械 | 127.6 | 35.6 | 2.09 | 2.67 | 0.3% | 21% | 41% | 34% | 2.6 | 2.4% | -3% | +26% | +29% | +6% | -42% | 53% | 29 |
| 益佰制药 600594 | 亏损或困境 | 中药Ⅱ | — | — | — | 1.39 | — | 50% | 70% | 42% | 177.8 | 3.9% | -12% | +12% | -6% | -20% | -42% | 46% | 29 |
| 冀衡医药 002742 | 重资产陷阱 | 化学制药 | — | — | — | 19.75 | — | — | 16% | 41% | — | -3.6% | -24% | +74% | -5% | +44% | -35% | 74% | 29 |
| 盘龙药业 002864 | 中性 | 中药Ⅱ | 37.4 | — | — | 1.69 | 1.3% | 26% | 58% | 18% | 0.4 | 5.0% | +5% | +3% | -9% | -9% | -36% | 41% | 29 |
| 科华生物 002022 | 亏损或困境 | 医疗器械 | — | — | — | 1.19 | — | — | 42% | 17% | — | -3.9% | -38% | -6% | -4% | -22% | -38% | 31% | 29 |
| 寿仙谷 603896 | 亏损或困境 | 中药Ⅱ | — | 26.6 | 1.27 | 1.33 | — | 30% | 83% | 33% | 2.8 | -5.2% | -8% | -7% | -23% | -34% | -42% | 27% | 29 |
| 南模生物 688265 | 亏损或困境 | 医疗服务 | 133.4 | — | — | 1.74 | 0.3% | 30% | 46% | 19% | 0.7 | -0.9% | +12% | +78% | -6% | -36% | -50% | 60% | 30 |
| 康芝药业 300086 | 亏损或困境 | 化学制药 | — | — | — | 3.44 | — | — | 54% | 40% | — | 0.9% | -4% | +146% | -46% | -7% | -59% | 70% | 30 |
| 山河药辅 300452 | 中性 | 化学制药 | 16.8 | — | — | 3.00 | 2.3% | 40% | 31% | 28% | 1.3 | 5.2% | +10% | +14% | -2% | -8% | -31% | 39% | 30 |
| 东宝生物 300239 | 中性 | 生物制品 | 55.2 | — | — | 1.75 | 0.2% | 13% | 23% | 48% | 3.1 | -0.9% | -8% | -6% | -13% | -15% | -32% | 35% | 30 |
| 汉邦科技 688755 | 中性 | 医疗器械 | 39.7 | — | — | 2.35 | 0.6% | 29% | 39% | 15% | 0.0 | 2.7% | +15% | — | -13% | -35% | -47% | 33% | 30 |
| 普蕊斯 301257 | 中性 | 医疗服务 | 52.2 | 21.9 | 1.15 | 2.40 | 0.4% | 11% | 26% | 1% | 0.0 | 0.1% | +13% | +94% | -26% | -1% | -55% | 69% | 30 |
| 凯因科技 688687 | 中性 | 生物制品 | 306.3 | — | — | 1.79 | 1.4% | 36% | 84% | 22% | 1.9 | 0.0% | +4% | +17% | -28% | -51% | -58% | 36% | 31 |
| 冠昊生物 300238 | 中性 | 医疗器械 | 178.1 | — | — | 5.25 | — | — | 77% | 42% | 3.0 | -0.2% | +1% | +15% | -17% | -34% | -42% | 44% | 31 |
| 贝瑞基因 000710 | 亏损或困境 | 医疗服务 | — | — | — | 2.18 | — | — | 45% | 19% | — | -2.1% | -12% | +34% | -22% | -47% | -54% | 48% | 31 |
| 海森药业 001367 | 轻资产现金牛 | 化学制药 | 22.1 | — | — | 2.01 | 0.6% | 14% | 41% | 14% | 0.0 | 4.1% | +8% | +20% | -7% | -23% | -38% | 36% | 31 |
| 海创药业 688302 | 亏损或困境 | 化学制药 | — | — | — | 3.08 | — | — | 54% | 28% | — | -5.3% | — | +60% | -36% | -50% | -50% | 50% | 31 |
| 祥生医疗 688358 | 现金流红利 | 医疗器械 | 27.3 | 22.2 | 1.11 | 2.31 | 3.1% | 79% | 59% | 9% | 0.0 | 2.4% | +5% | +30% | -3% | -15% | -37% | 50% | 32 |
| 利德曼 300289 | 亏损或困境 | 医疗器械 | — | — | — | 1.96 | — | 33% | 52% | 21% | 0.2 | 0.5% | -23% | +42% | -16% | -35% | -43% | 43% | 32 |
| ST复华 600624 | 亏损或困境 | 化学制药 | — | — | — | 7.89 | — | — | 42% | 28% | — | -2.4% | -7% | -20% | -11% | -36% | -56% | 38% | 32 |
| 之江生物 688317 | 亏损或困境 | 医疗器械 | — | — | — | 0.99 | — | — | 62% | 16% | — | 0.9% | -62% | +24% | -16% | -42% | -45% | 45% | 32 |
| 澳洋健康 002172 | 重资产陷阱 | 医疗服务 | 95.1 | — | — | 16.11 | — | — | 14% | 41% | 6.6 | -0.2% | -4% | +27% | +6% | -1% | -40% | 47% | 32 |
| 赛科希德 688338 | 中性 | 医疗器械 | 38.6 | 35.1 | 2.34 | 1.90 | 0.8% | 31% | 62% | 17% | — | 1.5% | +5% | +9% | +19% | +10% | -33% | 46% | 32 |
| 海特生物 300683 | 亏损或困境 | 医疗服务 | — | — | — | 1.56 | — | — | 43% | 26% | — | -1.9% | -8% | +17% | -10% | -58% | -58% | 62% | 33 |
| 维力医疗 603309 | 现金流红利 | 医疗器械 | 57.5 | 12.4 | 0.65 | 1.85 | 4.4% | 76% | 44% | 26% | 1.6 | 7.5% | +6% | +19% | -14% | -21% | -29% | 34% | 33 |
| 北大医药 000788 | 纯久期 | 化学制药 | 86.0 | — | — | 2.17 | 3.6% | 35% | 32% | 6% | 0.5 | 17.4% | -11% | +3% | -7% | -14% | -35% | 43% | 33 |
| 诚意药业 603811 | 中性 | 化学制药 | 18.6 | — | — | 2.33 | 3.0% | 41% | 70% | 50% | 0.3 | 6.4% | +7% | +42% | -1% | -30% | -33% | 32% | 33 |
| 康德莱 603987 | 中性 | 医疗器械 | 14.5 | — | — | 1.17 | 2.2% | 31% | 33% | 29% | 1.5 | 10.3% | -10% | +23% | -10% | -12% | -28% | 27% | 33 |
| 戴维医疗 300314 | 中性 | 医疗器械 | 55.2 | — | — | 2.70 | 0.7% | 35% | 58% | 25% | 0.0 | 1.6% | +5% | +13% | -8% | -25% | -40% | 42% | 33 |
| 华仁药业 300110 | 亏损或困境 | 化学制药 | — | — | — | 3.83 | — | 13% | 43% | 38% | 5.7 | 8.2% | -7% | -10% | -11% | -22% | -32% | 31% | 33 |
| 硕世生物 688399 | 亏损或困境 | 医疗器械 | — | — | — | 1.14 | 8.5% | — | 63% | 18% | 18.8 | -1.6% | -61% | +67% | -42% | -35% | -58% | 58% | 33 |
| 易明医药 002826 | 中性 | 化学制药 | 27.7 | — | — | 3.91 | 0.8% | 38% | 51% | 27% | 0.2 | 6.7% | -9% | +80% | -3% | -20% | -32% | 43% | 34 |
| 德源药业 920735 | 中性 | 化学制药 | 12.7 | — | — | 2.44 | 1.4% | 20% | 82% | 32% | 0.0 | 4.0% | +18% | +64% | -14% | — | — | — | 34 |
| 康众医疗 688607 | 亏损或困境 | 医疗器械 | — | 178.6 | 2.03 | 4.07 | — | 31% | 40% | 15% | — | -2.5% | +16% | +224% | -10% | +32% | -54% | 69% | 34 |
| 中关村 000931 | 亏损或困境 | 化学制药 | — | — | — | 2.14 | 0.4% | 31% | 58% | 26% | 3.8 | 0.5% | +6% | +2% | -7% | -19% | -32% | 37% | 34 |
| 奥泰生物 688606 | 现金流红利 | 医疗器械 | 24.9 | — | — | 0.92 | 4.5% | 78% | 55% | 25% | 0.1 | 1.7% | -36% | +5% | -27% | -38% | -44% | 28% | 35 |
| 威尔药业 603351 | 中性 | 化学制药 | 22.5 | 20.2 | 1.55 | 1.95 | 2.3% | 37% | 28% | 56% | 1.3 | 6.0% | +6% | +8% | +1% | -13% | -23% | 33% | 35 |
| 健尔康 603205 | 中性 | 医疗器械 | 30.8 | — | — | 2.32 | 1.1% | 31% | 24% | 23% | 0.1 | 2.0% | -2% | -2% | -21% | -26% | -37% | 26% | 35 |
| 金凯生科 301509 | 现金流红利 | 医疗服务 | 55.8 | — | — | 1.66 | 3.1% | 103% | 42% | 15% | 0.0 | 2.2% | -4% | +34% | -11% | -32% | -43% | 48% | 35 |
| 美康生物 300439 | 中性 | 医疗器械 | 52.1 | — | — | 1.18 | 0.4% | 20% | 40% | 30% | 0.4 | 2.3% | -15% | -4% | -6% | -19% | -31% | 27% | 36 |
| 嘉事堂 002462 | 中性 | 医药商业 | 39.5 | — | — | 0.81 | 0.9% | 30% | 7% | 2% | 3.8 | 37.8% | -9% | +13% | -14% | -16% | -44% | 39% | 36 |
| 粤万年青 301111 | 纯久期 | 中药Ⅱ | 608.1 | — | — | 4.83 | 0.2% | 107% | 69% | 5% | 4.0 | -0.0% | +4% | +17% | +19% | +29% | -45% | 73% | 36 |
| *ST明德 002932 | 亏损或困境 | 医疗器械 | — | — | — | 0.67 | — | 204% | 54% | 11% | — | -2.4% | -71% | +12% | -19% | -28% | -36% | 28% | 36 |
| 双成药业 002693 | 亏损或困境 | 化学制药 | 71.0 | — | — | 8.52 | — | — | 68% | 49% | 1.8 | 0.9% | +0% | -62% | +26% | +7% | -29% | 48% | 36 |
| 迈普医学 301033 | 中性 | 医疗器械 | 29.7 | 24.7 | 0.71 | 4.48 | 1.3% | 50% | 82% | 33% | 0.1 | 2.7% | +24% | +64% | -19% | -35% | -45% | 53% | 36 |
| 盟科药业 688373 | 亏损或困境 | 化学制药 | — | — | — | 22.35 | — | — | 83% | 0% | — | -3.2% | +43% | +22% | -8% | -28% | -57% | 52% | 36 |
| 海辰药业 300584 | 中性 | 化学制药 | 81.7 | — | — | 3.42 | 0.3% | 28% | 81% | 56% | 1.7 | -0.8% | +8% | +151% | -39% | -48% | -61% | 66% | 37 |
| *ST未名 002581 | 亏损或困境 | 生物制品 | — | — | — | 2.09 | — | — | 79% | 17% | — | -9.4% | -8% | -30% | -25% | -23% | -65% | 52% | 37 |
| 拱东医疗 605369 | 中性 | 医疗器械 | 66.6 | 28.7 | 1.91 | 2.19 | 0.9% | 92% | 33% | 30% | 1.1 | 4.4% | -8% | -6% | -9% | -17% | -32% | 34% | 37 |
| 赛伦生物 688163 | 中性 | 生物制品 | 68.3 | — | — | 3.32 | 1.1% | 78% | 78% | 20% | 0.1 | 0.6% | +4% | +27% | +60% | +36% | -50% | 55% | 37 |
| 灵康药业 603669 | 亏损或困境 | 化学制药 | — | — | — | 6.40 | — | — | 47% | 35% | — | -3.0% | +4% | -13% | +14% | -17% | -39% | 47% | 37 |
| 润都股份 002923 | 中性 | 化学制药 | 276.2 | — | — | 3.45 | — | 112% | 51% | 50% | 2.1 | 4.0% | -5% | +29% | -9% | -24% | -46% | 44% | 37 |
| 安旭生物 688075 | 纯久期 | 医疗器械 | — | — | — | 0.74 | 2.7% | 80% | 42% | 14% | 2.9 | -3.4% | -58% | +7% | -23% | -30% | -38% | 26% | 37 |
| 凯普生物 300639 | 亏损或困境 | 医疗器械 | — | — | — | 1.00 | — | 26% | 61% | 30% | 0.7 | 5.4% | -51% | -9% | +10% | -12% | -45% | 50% | 38 |
| ST海王 000078 | 亏损或困境 | 医药商业 | — | — | — | 3.73 | — | — | 10% | 4% | 57.9 | 0.2% | -11% | +36% | -58% | -48% | -76% | 69% | 38 |
| 东方生物 688298 | 亏损或困境 | 医疗器械 | — | — | — | 0.66 | — | — | 43% | 38% | — | -10.5% | -52% | -20% | -19% | -36% | -41% | 34% | 38 |
| 司太立 603520 | 现金流红利 | 化学制药 | 183.1 | 29.6 | 0.37 | 1.55 | 3.4% | 1500% | 24% | 49% | 7.6 | -5.6% | +5% | +10% | -4% | -23% | -41% | 43% | 38 |
| 哈三联 002900 | 亏损或困境 | 化学制药 | — | — | — | 2.24 | — | 94% | 60% | 45% | — | -4.7% | -8% | +29% | -2% | -20% | -39% | 52% | 39 |
| 康惠股份 603139 | 亏损或困境 | 中药Ⅱ | — | — | — | 7.27 | — | — | 31% | 48% | — | -3.0% | -1% | +42% | +79% | +51% | -34% | 49% | 39 |
| 乐心医疗 300562 | 中性 | 医疗器械 | 39.1 | — | — | 3.47 | 0.7% | 95% | 31% | 14% | 0.4 | 3.9% | -2% | -9% | +35% | +10% | -30% | 42% | 39 |
| 塞力医疗 603716 | 亏损或困境 | 医药商业 | — | — | — | 3.58 | — | — | 20% | 6% | — | 0.1% | -22% | +185% | -16% | -50% | -63% | 60% | 39 |
| 沃华医药 002107 | 现金流红利 | 中药Ⅱ | 33.2 | — | — | 5.57 | 3.9% | 203% | 75% | 33% | 0.0 | 3.4% | -7% | +36% | +14% | +3% | -31% | 44% | 39 |
| 卫信康 603676 | 定价权·品牌 | 化学制药 | 20.5 | — | — | 2.56 | 3.6% | 60% | 53% | 20% | 0.0 | 4.0% | -7% | +10% | -12% | -27% | -37% | 28% | 40 |
| 新天地 301277 | 中性 | 化学制药 | 38.0 | — | — | 2.58 | 2.0% | 64% | 40% | 36% | 0.0 | 1.0% | +2% | +23% | -13% | -31% | -40% | 38% | 40 |
| 向日葵 300111 | 亏损或困境 | 化学制药 | — | — | — | 5.92 | — | — | 25% | 8% | 1.1 | -0.8% | -7% | +89% | -50% | -20% | -72% | 80% | 40 |
| 宝莱特 300246 | 亏损或困境 | 医疗器械 | — | — | — | 3.78 | 0.3% | — | 30% | 38% | 16.2 | 2.2% | -3% | +24% | +85% | +59% | -36% | 71% | 40 |
| 陇神戎发 300534 | 中性 | 中药Ⅱ | 115.9 | — | — | 5.59 | 0.3% | 28% | 64% | 39% | 1.0 | 0.3% | +29% | +10% | +40% | +21% | -36% | 64% | 40 |
| 四环生物 000518 | 亏损或困境 | 生物制品 | — | — | — | 13.00 | — | — | 69% | 11% | — | 0.2% | +8% | -5% | +62% | +55% | -32% | 45% | 40 |
| 亚太药业 002370 | 亏损或困境 | 化学制药 | — | — | — | 3.59 | — | — | 33% | 24% | — | -1.9% | -5% | +140% | -26% | -20% | -49% | 52% | 40 |
| 立方制药 003020 | 中性 | 化学制药 | 24.8 | — | — | 2.20 | 2.4% | 58% | 52% | 37% | 0.3 | 4.0% | -16% | +50% | -17% | -44% | -51% | 46% | 40 |
| 金陵药业 000919 | 中性 | 化学制药 | 72.9 | — | — | 1.08 | 1.5% | 115% | 21% | 23% | 0.8 | 6.7% | +6% | +23% | -16% | -8% | -34% | 35% | 41 |
| 小方制药 603207 | 现金流红利 | 化学制药 | 21.2 | — | — | 3.57 | 4.2% | 90% | 65% | 27% | 0.0 | 2.0% | +5% | +11% | -11% | -27% | -39% | 32% | 41 |
| 国科恒泰 301370 | 纯久期 | 医疗器械 | 152.8 | — | — | 1.66 | 1.4% | 33% | 12% | 9% | 7.8 | 10.7% | +3% | +9% | -25% | -23% | -35% | 28% | 41 |
| 科兴制药 688136 | 亏损或困境 | 生物制品 | 19.6 | 23.9 | 0.92 | 2.24 | 1.2% | 66% | 71% | 29% | 17.9 | -0.2% | +5% | +46% | -35% | -55% | -62% | 54% | 41 |
| 安杰思 688581 | 定价权·品牌 | 医疗器械 | 19.3 | 17.0 | 1.13 | 1.62 | 2.0% | 38% | 71% | 8% | 0.3 | 3.6% | +17% | +0% | -11% | -38% | -38% | 32% | 41 |
| 宣泰医药 688247 | 中性 | 化学制药 | 130.7 | — | — | 3.13 | 0.4% | 32% | 56% | 24% | 0.0 | 2.5% | +22% | -3% | -6% | -25% | -38% | 40% | 41 |
| 博晖创新 300318 | 亏损或困境 | 生物制品 | — | — | — | 3.26 | — | — | 41% | 34% | 11.7 | -6.0% | +1% | +10% | -19% | -20% | -49% | 44% | 41 |
| 澳华内镜 688212 | 亏损或困境 | 医疗器械 | — | 96.0 | 0.79 | 3.40 | — | 85% | 69% | 33% | 7.7 | -2.3% | +20% | +9% | -29% | -39% | -51% | 39% | 42 |
| 赛升药业 300485 | 亏损或困境 | 生物制品 | — | — | — | 1.30 | 0.3% | 55% | 70% | 13% | 0.6 | -1.9% | -18% | +51% | -18% | -40% | -42% | 48% | 42 |
| 兰卫医学 301060 | 亏损或困境 | 医疗服务 | 108.2 | — | — | 2.70 | 1.7% | — | 24% | 18% | 0.6 | 8.0% | -30% | +4% | +15% | +0% | -40% | 53% | 42 |
| 和元生物 688238 | 重资产陷阱 | 医疗服务 | — | — | — | 3.22 | — | — | -7% | 65% | — | -4.4% | -3% | +35% | -3% | -24% | -39% | 55% | 42 |
| 永安药业 002365 | 中性 | 化学制药 | 79.1 | 43.5 | 3.62 | 2.11 | 0.7% | 88% | 23% | 40% | 0.0 | 0.0% | -19% | +90% | -3% | -28% | -49% | 43% | 42 |
| 济民健康 603222 | 亏损或困境 | 医疗器械 | — | — | — | 3.88 | — | — | 42% | 54% | — | -0.3% | -6% | +34% | -12% | -19% | -50% | 61% | 42 |
| 伟思医疗 688580 | 中性 | 医疗器械 | 25.1 | 24.5 | 2.72 | 2.51 | 2.4% | 75% | 72% | 25% | 0.0 | 0.4% | +13% | +82% | -6% | -19% | -36% | 54% | 42 |
| 鹭燕医药 002788 | 中性 | 医药商业 | 15.8 | — | — | 1.29 | 3.2% | 39% | 8% | 15% | 7.5 | 4.1% | +3% | +177% | -47% | +30% | -66% | 64% | 43 |
| 健民集团 600976 | 轻资产现金牛 | 中药Ⅱ | 13.6 | 11.0 | 0.61 | 1.60 | 3.2% | 38% | 46% | 14% | 0.3 | 5.1% | -2% | -18% | -14% | -31% | -41% | 28% | 43 |
| 力生制药 002393 | 现金流红利 | 化学制药 | 28.4 | — | — | 0.96 | 5.4% | 49% | 58% | 18% | 0.1 | 2.3% | +7% | +27% | -19% | -31% | -32% | 29% | 43 |
| ST中珠 600568 | 亏损或困境 | 医疗服务 | — | — | — | 2.71 | — | — | 25% | 14% | — | -0.3% | +4% | +93% | -14% | +14% | -36% | 40% | 43 |
| *ST香雪 300147 | 亏损或困境 | 中药Ⅱ | — | — | — | — | — | — | 26% | 53% | 11.3 | 1.6% | -10% | -7% | -28% | -37% | -47% | 50% | 43 |
| 近岸蛋白 688137 | 亏损或困境 | 生物制品 | — | — | — | 2.17 | — | 278% | 76% | 8% | — | -2.3% | -18% | +21% | +55% | +36% | -38% | 68% | 43 |
| 佛慈制药 002644 | 中性 | 中药Ⅱ | 73.9 | — | — | 2.34 | 0.2% | 21% | 31% | 37% | 0.2 | 6.7% | -4% | +12% | -1% | -9% | -32% | 32% | 44 |
| 森萱医药 920946 | 中性 | 化学制药 | 28.5 | 26.3 | 1.75 | 3.40 | 1.6% | 51% | 45% | 20% | 0.1 | 4.6% | -4% | +21% | -1% | — | — | — | 44 |
| 金石亚药 300434 | 中性 | 化学制药 | 27.4 | — | — | 1.69 | 0.7% | 30% | 58% | 26% | 0.4 | 1.8% | -6% | +26% | +8% | +3% | -32% | 49% | 44 |
| 民生健康 301507 | 中性 | 化学制药 | 37.0 | 39.5 | 0.99 | 2.75 | 1.2% | 38% | 60% | 27% | 0.0 | -0.2% | +13% | +22% | -18% | -18% | -35% | 34% | 44 |
| 诺思兰德 920047 | 亏损或困境 | 生物制品 | — | — | — | 17.88 | — | — | 56% | 48% | — | -1.9% | +1% | +106% | -32% | — | — | — | 44 |
| 联环药业 600513 | 亏损或困境 | 化学制药 | — | — | — | 3.52 | 0.4% | 31% | 49% | 36% | 13.6 | -4.3% | +12% | +87% | -15% | -38% | -54% | 60% | 44 |
| 山外山 688410 | 成长兑现 | 医疗器械 | 24.2 | 16.6 | 0.50 | 2.47 | 1.4% | 45% | 45% | 20% | 0.0 | 0.5% | +28% | +36% | -5% | -13% | -27% | 42% | 45 |
| 康泰医学 300869 | 亏损或困境 | 医疗器械 | — | — | — | 2.73 | — | 73% | 49% | 11% | — | -0.1% | -13% | +10% | -25% | -40% | -44% | 29% | 45 |
| 睿智医药 300149 | 亏损或困境 | 医疗服务 | — | — | — | 3.54 | — | — | 26% | 16% | 2.7 | 2.2% | -5% | +49% | -7% | -34% | -46% | 63% | 45 |
| ST凯利 300326 | 轻资产现金牛 | 医疗器械 | 20.1 | — | — | 1.56 | 1.6% | 46% | 54% | 6% | 0.3 | 4.5% | -6% | -13% | +13% | +10% | -26% | 30% | 45 |
| 百花医药 600721 | 纯久期 | 医疗服务 | 153.2 | — | — | 5.73 | 0.3% | 38% | 46% | 13% | — | 0.5% | +4% | +86% | -2% | +28% | -47% | 63% | 46 |
| 特一药业 002728 | 中性 | 中药Ⅱ | 61.6 | — | — | 2.59 | 1.7% | 94% | 53% | 30% | 2.9 | 2.4% | +1% | +22% | -16% | -3% | -47% | 52% | 46 |
| 亚宝药业 600351 | 现金流红利 | 中药Ⅱ | 14.3 | — | — | 1.63 | 8.3% | 76% | 56% | 31% | 0.1 | 12.3% | -6% | +13% | +12% | -2% | -18% | 28% | 46 |
| 开开实业 600272 | 纯久期 | 医药商业 | 197.5 | — | — | 5.81 | 0.1% | 31% | 21% | 13% | 0.3 | 1.5% | +8% | -10% | +29% | +27% | -44% | 55% | 46 |
| 福安药业 300194 | 中性 | 化学制药 | 77.4 | — | — | 1.05 | 1.8% | 26% | 53% | 29% | 1.9 | 7.6% | -10% | +1% | -11% | -19% | -30% | 26% | 46 |
| 基蛋生物 603387 | 中性 | 医疗器械 | 15.9 | — | — | 1.60 | 2.6% | 41% | 67% | 19% | 0.9 | 6.6% | -17% | +4% | +13% | +8% | -28% | 38% | 47 |
| 方盛制药 603998 | 现金流红利 | 中药Ⅱ | 14.2 | 13.0 | 0.65 | 2.67 | 4.2% | 64% | 68% | 36% | 0.7 | 9.1% | -1% | +13% | -1% | -11% | -30% | 33% | 47 |
| 百诚医药 301096 | 亏损或困境 | 医疗服务 | — | — | — | 1.91 | — | 12% | 66% | 46% | 9.7 | -3.1% | +4% | +51% | -24% | -22% | -48% | 53% | 47 |
| 太龙药业 600222 | 纯久期 | 中药Ⅱ | 90.3 | — | — | 2.95 | 0.2% | 22% | 27% | 12% | 6.6 | 1.7% | -4% | +29% | +30% | +24% | -26% | 48% | 48 |
| 康辰药业 603590 | 中性 | 生物制品 | 28.0 | 25.8 | 1.61 | 1.50 | 1.2% | 33% | 89% | 9% | 1.6 | 1.7% | +2% | +75% | -24% | -43% | -55% | 50% | 48 |
| 三鑫医疗 300453 | 现金流红利 | 医疗器械 | 17.0 | — | — | 3.21 | 3.3% | 59% | 35% | 49% | 0.5 | 4.1% | +7% | +22% | +8% | -8% | -19% | 31% | 48 |
| 普门科技 688389 | 定价权·品牌 | 医疗器械 | 33.8 | 22.2 | 1.01 | 2.31 | 2.5% | 36% | 63% | 22% | 1.2 | 4.0% | +2% | -11% | -12% | -21% | -34% | 26% | 48 |
| 博济医药 300404 | 纯久期 | 医疗服务 | 92.0 | — | — | 4.42 | 0.1% | 16% | 33% | 12% | 0.6 | 1.1% | +27% | +7% | +33% | +6% | -36% | 54% | 48 |
| 神奇制药 600613 | 中性 | 化学制药 | 175.8 | — | — | 2.10 | 0.8% | 100% | 50% | 34% | 0.3 | 3.2% | -6% | -10% | +50% | +30% | -36% | 44% | 48 |
| 首药控股 688197 | 亏损或困境 | 化学制药 | — | — | — | 7.79 | — | — | 99% | 2% | — | -2.4% | +68% | +16% | -7% | -38% | -41% | 55% | 48 |
| 键凯科技 688356 | 中性 | 化学制药 | 113.7 | — | — | 3.73 | 0.4% | 30% | 81% | 32% | 0.0 | 0.4% | -8% | +45% | -3% | -19% | -45% | 66% | 48 |
| 亨迪药业 301211 | 中性 | 化学制药 | 104.2 | — | — | 2.13 | 0.5% | 78% | 29% | 22% | 0.0 | -0.6% | -4% | -16% | -5% | -10% | -42% | 56% | 48 |
| 瑞康医药 002589 | 纯久期 | 医药商业 | 536.0 | — | — | 0.91 | 0.1% | 80% | 11% | 12% | 18.3 | 0.6% | -16% | +9% | +0% | +5% | -48% | 52% | 48 |
| 维康药业 300878 | 亏损或困境 | 中药Ⅱ | — | — | — | 5.47 | — | — | 50% | 58% | — | -1.2% | -25% | +71% | +31% | +48% | -34% | 72% | 49 |
| 汉森制药 002412 | 现金流红利 | 中药Ⅱ | 20.6 | — | — | 2.08 | 3.1% | 76% | 73% | 18% | 0.0 | 3.6% | +4% | +7% | +58% | +45% | -31% | 49% | 49 |
| 多瑞医药 301075 | 亏损或困境 | 化学制药 | — | — | — | 7.42 | — | 52% | 69% | 54% | — | -3.9% | -27% | +232% | +2% | +43% | -52% | 63% | 49 |
| 北陆药业 300016 | 中性 | 化学制药 | 34.6 | — | — | 1.97 | — | 167% | 48% | 32% | 2.5 | 1.0% | +16% | +29% | +7% | -18% | -35% | 50% | 49 |
| 三力制药 603439 | 定价权·品牌 | 中药Ⅱ | 13198.2 | — | — | 3.37 | 0.5% | 51% | 70% | 18% | 2.8 | 4.6% | +12% | -8% | +5% | -6% | -43% | 38% | 49 |
| 三友医疗 688085 | 纯久期 | 医疗器械 | 92.6 | 47.9 | 0.96 | 2.35 | 0.1% | 10% | 80% | 13% | 0.3 | 1.0% | -6% | +2% | -16% | -33% | -51% | 46% | 50 |
| 卫光生物 002880 | 中性 | 生物制品 | 27.5 | — | — | 2.09 | 0.9% | 18% | 41% | 17% | 2.1 | -1.2% | +24% | -5% | -12% | -24% | -39% | 37% | 50 |
| 金城医药 300233 | 中性 | 化学制药 | 36.1 | — | — | 1.34 | 1.9% | 77% | 44% | 40% | 0.7 | 6.0% | -8% | +21% | -5% | -32% | -43% | 36% | 50 |
| 普瑞眼科 301239 | 亏损或困境 | 医疗服务 | 403.7 | 35.7 | 0.46 | 2.37 | — | 22% | 42% | 27% | 3.2 | 7.4% | +18% | -30% | +3% | -24% | -38% | 41% | 51 |
| 科源制药 301281 | 中性 | 化学制药 | 131.3 | — | — | 3.54 | 0.1% | 36% | 44% | 36% | 1.8 | -1.0% | -4% | -1% | +60% | +27% | -46% | 60% | 51 |
| 吉贝尔 688566 | 中性 | 化学制药 | 24.3 | 20.8 | 0.95 | 2.05 | 2.0% | 64% | 89% | 38% | 0.0 | 2.7% | +14% | +37% | -14% | -34% | -45% | 35% | 51 |
| 万邦医药 301520 | 纯久期 | 医疗服务 | 531.3 | — | — | 3.47 | 0.4% | 27% | 49% | 11% | — | -0.6% | +2% | +4% | +98% | +69% | -37% | 80% | 52 |
| 罗欣药业 002793 | 亏损或困境 | 化学制药 | — | 43.4 | 0.38 | 4.61 | — | — | 46% | 19% | 15.1 | 6.0% | -14% | +26% | -1% | -18% | -35% | 44% | 52 |
| 珍宝岛 603567 | 亏损或困境 | 中药Ⅱ | — | — | — | 0.86 | — | 36% | 33% | 13% | — | 8.6% | -43% | -22% | -38% | -56% | -66% | 52% | 52 |
| 圣诺生物 688117 | 成长兑现 | 化学制药 | 25.5 | 20.0 | 0.71 | 4.54 | 1.1% | 32% | 64% | 38% | 1.8 | 0.9% | +23% | +110% | -12% | -24% | -34% | 47% | 52 |
| 振东制药 300158 | 亏损或困境 | 中药Ⅱ | — | — | — | 1.61 | — | — | 50% | 26% | — | -10.5% | -9% | +34% | -9% | -41% | -52% | 46% | 52 |
| 毕得医药 688073 | 成长兑现 | 医疗服务 | 29.3 | 24.3 | 1.06 | 2.58 | 1.9% | 68% | 44% | 4% | 0.4 | 1.5% | +17% | +27% | -2% | -11% | -44% | 67% | 53 |
| 漱玉平民 301017 | 中性 | 医药商业 | 51.4 | — | — | 2.67 | 0.3% | 16% | 28% | 8% | 5.2 | 11.0% | +10% | +24% | -11% | +3% | -44% | 63% | 53 |
| 泓博医药 301230 | 纯久期 | 医疗服务 | 140.0 | — | — | 5.29 | 1.0% | 148% | 31% | 16% | 1.2 | 1.9% | +13% | +19% | +30% | -6% | -55% | 73% | 54 |
| 合富中国 603122 | 亏损或困境 | 医药商业 | — | — | — | 5.20 | — | 211% | 20% | 10% | — | -1.2% | -19% | +255% | -44% | +90% | -68% | 72% | 54 |
| 昂利康 002940 | 中性 | 化学制药 | 47.4 | — | — | 3.28 | 0.9% | 31% | 45% | 20% | 1.6 | 4.4% | -3% | +161% | -19% | -52% | -56% | 65% | 54 |
| 诺思格 301333 | 中性 | 医疗服务 | 45.1 | 35.6 | 2.23 | 2.71 | 0.3% | 11% | 37% | 1% | 0.3 | 0.8% | +10% | +20% | -5% | +1% | -51% | 63% | 54 |
| 春立医疗 688236 | 轻资产现金牛 | 医疗器械 | 19.6 | 16.6 | 0.75 | 1.79 | 2.5% | 50% | 72% | 13% | 0.0 | 4.4% | -4% | +82% | -37% | -37% | -54% | 44% | 54 |
| 诚达药业 301201 | 亏损或困境 | 医疗服务 | — | — | — | 2.61 | 0.6% | 34% | 44% | 34% | 0.7 | 0.1% | -0% | +105% | -13% | +10% | -57% | 74% | 55 |
| 九典制药 300705 | 中性 | 化学制药 | 16.2 | 18.4 | 0.88 | 2.16 | 3.6% | 30% | 77% | 39% | 1.1 | 0.1% | +10% | -15% | -24% | -42% | -50% | 32% | 55 |
| 采纳股份 301122 | 中性 | 医疗器械 | 903.8 | 63.9 | 2.56 | 2.93 | 0.1% | 58% | 39% | 33% | 2.4 | -1.2% | -8% | +30% | +74% | +90% | -32% | 60% | 55 |
| 奥美医疗 002950 | 中性 | 医疗器械 | 22.9 | — | — | 1.51 | 1.6% | 16% | 29% | 33% | 1.4 | -0.3% | -4% | +26% | -18% | -8% | -41% | 48% | 56 |
| 迈克生物 300463 | 亏损或困境 | 医疗器械 | — | 73.9 | 0.74 | 0.89 | — | 40% | 55% | 48% | 2.5 | 1.3% | -16% | -15% | -17% | -28% | -43% | 32% | 56 |
| 博拓生物 688767 | 中性 | 医疗器械 | 275.9 | 54.6 | 2.60 | 2.62 | 1.9% | 186% | 53% | 24% | 1.8 | -1.3% | -38% | +70% | +1% | -7% | -37% | 61% | 56 |
| 上海凯宝 300039 | 中性 | 中药Ⅱ | 21.7 | — | — | 1.31 | 2.4% | 32% | 80% | 6% | 0.0 | 2.9% | +1% | -0% | -9% | -20% | -37% | 42% | 56 |
| 津药药业 600488 | 中性 | 化学制药 | 87.3 | — | — | 1.86 | 1.0% | 80% | 46% | 45% | 1.5 | 4.6% | -8% | -1% | +28% | +16% | -44% | 65% | 56 |
| 莱美药业 300006 | 亏损或困境 | 化学制药 | — | — | — | 3.28 | — | — | 69% | 9% | — | 0.3% | -4% | +40% | +4% | +10% | -32% | 58% | 57 |
| ST万邦 002082 | 亏损或困境 | 中药Ⅱ | — | — | — | 2.20 | — | 100% | 42% | 34% | 13.9 | 8.7% | -14% | +117% | -34% | +17% | -75% | 64% | 57 |
| 华强科技 688151 | 纯久期 | 医疗器械 | 119.0 | — | — | 1.36 | 0.3% | 47% | 23% | 13% | — | 0.5% | +2% | +33% | -19% | -34% | -44% | 38% | 57 |
| 华人健康 301408 | 中性 | 医药商业 | 25.8 | — | — | 2.72 | 0.7% | 29% | 33% | 9% | 1.9 | 10.4% | +19% | +70% | -22% | -3% | -56% | 70% | 58 |
| 英特集团 000411 | 中性 | 医药商业 | 12.9 | — | — | 1.05 | 3.5% | 37% | 7% | 7% | 3.9 | 7.5% | +3% | +25% | -18% | -7% | -38% | 40% | 58 |
| 亚辉龙 688575 | 中性 | 医疗器械 | 86.0 | 34.1 | 1.18 | 2.10 | 0.2% | 43% | 57% | 39% | 1.8 | 2.8% | -23% | -9% | -29% | -38% | -48% | 33% | 58 |
| 诺禾致源 688315 | 中性 | 医疗服务 | 38.4 | — | — | 2.17 | 0.3% | 11% | 43% | 17% | 0.3 | 3.8% | +5% | +7% | +5% | -15% | -30% | 45% | 58 |
| 瑞迈特 301367 | 中性 | 医疗器械 | 26.4 | 16.3 | 0.65 | 1.90 | 1.0% | 23% | 46% | 1% | 0.6 | 2.3% | -6% | +37% | -24% | -32% | -44% | 47% | 58 |
| 信邦制药 002390 | 中性 | 中药Ⅱ | 51.8 | — | — | 0.86 | 2.9% | 120% | 19% | 27% | 1.0 | 14.7% | -4% | -29% | -5% | -18% | -36% | 34% | 58 |
| 人民同泰 600829 | 中性 | 医药商业 | 41.1 | — | — | 1.89 | — | 29% | 10% | 3% | 2.5 | -0.3% | +2% | +44% | -7% | +21% | -56% | 62% | 58 |
| ST能特 002102 | 亏损或困境 | 化学制药 | — | — | — | 1.94 | — | — | 3% | 15% | 5.4 | -17.7% | -16% | +27% | -27% | -43% | -55% | 37% | 58 |
| 华特达因 000915 | 定价权·品牌 | 化学制药 | 14.1 | 10.5 | 1.17 | 2.27 | 9.8% | 110% | 84% | 19% | — | 8.4% | -2% | +31% | -18% | -21% | -30% | 24% | 59 |
| 润达医疗 603108 | 亏损或困境 | 医药商业 | — | — | — | 1.62 | — | 27% | 27% | 7% | 13.0 | 8.0% | -13% | -6% | -34% | -48% | -56% | 48% | 60 |
| 蓝帆医疗 002382 | 重资产陷阱 | 医疗器械 | — | 12.4 | 0.83 | 0.84 | — | — | 16% | 32% | 3.2 | 3.1% | +5% | +9% | +6% | -9% | -41% | 37% | 60 |
| 昊帆生物 301393 | 中性 | 生物制品 | 55.0 | — | — | 2.51 | 0.7% | 38% | 40% | 29% | 0.7 | -3.7% | +10% | +28% | +10% | -6% | -28% | 50% | 60 |
| 双鹭药业 002038 | 轻资产现金牛 | 化学制药 | — | — | — | 1.23 | 0.2% | 37% | 82% | 10% | — | 8.2% | -16% | -1% | -20% | -28% | -44% | 55% | 60 |
| 楚天科技 300358 | 中性 | 医疗器械 | 14.7 | — | — | 1.08 | 0.8% | 17% | 32% | 21% | 1.6 | 12.9% | -4% | +43% | -13% | -4% | -38% | 48% | 60 |
| 华森制药 002907 | 中性 | 中药Ⅱ | 81.6 | — | — | 3.48 | 0.5% | 48% | 57% | 23% | 0.2 | 1.0% | +2% | +15% | -2% | -21% | -36% | 39% | 61 |
| 悦康药业 688658 | 亏损或困境 | 化学制药 | — | — | — | 1.90 | — | 98% | 63% | 38% | 10.6 | 4.2% | -19% | +57% | -40% | -59% | -64% | 67% | 61 |
| 正川股份 603976 | 中性 | 医疗器械 | 359.4 | — | — | 5.25 | 0.7% | 99% | 21% | 41% | 2.8 | 1.6% | -6% | +22% | +88% | +64% | -23% | 46% | 61 |
| 柳药集团 603368 | 中性 | 医药商业 | 9.6 | — | — | 0.79 | 4.2% | 34% | 11% | 6% | 3.5 | 15.4% | +3% | +4% | -8% | -13% | -26% | 23% | 62 |
| 海南海药 000566 | 亏损或困境 | 化学制药 | — | — | — | — | — | — | 39% | 41% | — | -2.1% | -22% | +49% | -32% | -21% | -58% | 66% | 63 |
| 精华制药 002349 | 中性 | 中药Ⅱ | 28.3 | — | — | 2.25 | 1.2% | 30% | 49% | 15% | 0.0 | 4.7% | -2% | -4% | +7% | -1% | -26% | 32% | 64 |
| 翔宇医疗 688626 | 中性 | 医疗器械 | 77.8 | 65.5 | 2.52 | 3.05 | 0.4% | 36% | 67% | 43% | 4.6 | -0.5% | +16% | +108% | -34% | -35% | -54% | 57% | 64 |
| ST百灵 002424 | 亏损或困境 | 中药Ⅱ | — | — | — | 2.01 | — | — | 58% | 22% | 4.0 | 7.1% | -5% | +13% | +6% | -27% | -34% | 34% | 64 |
| 昆药集团 600422 | 亏损或困境 | 中药Ⅱ | — | — | — | 1.32 | 2.1% | 35% | 42% | 10% | — | -8.6% | -7% | -20% | -31% | -41% | -49% | 28% | 64 |
| 奥翔药业 603229 | 中性 | 化学制药 | 79.8 | — | — | 2.71 | 0.8% | 40% | 54% | 33% | 2.3 | -0.4% | +1% | +0% | -21% | -36% | -39% | 32% | 65 |
| 千金药业 600479 | 成长兑现 | 中药Ⅱ | 19.1 | 17.1 | 1.07 | 2.14 | 2.9% | 57% | 46% | 11% | 0.3 | 7.1% | -3% | -2% | +34% | +20% | -18% | 33% | 65 |
| 艾迪药业 688488 | 亏损或困境 | 生物制品 | — | 140.4 | 1.11 | 7.10 | — | — | 46% | 20% | 5.6 | -0.6% | +43% | +108% | -6% | -15% | -48% | 60% | 65 |
| 前沿生物 688221 | 亏损或困境 | 化学制药 | — | — | — | 6.31 | — | — | 29% | 24% | 32.8 | 0.7% | +13% | +85% | -4% | -5% | -40% | 77% | 65 |
| 华康洁净 301235 | 中性 | 医疗器械 | 58.0 | 24.3 | 0.53 | 3.41 | 0.3% | 10% | 37% | 10% | 5.2 | -3.4% | +24% | +84% | +28% | +39% | -56% | 81% | 65 |
| 辰欣药业 603367 | 中性 | 化学制药 | 14.4 | — | — | 1.03 | 2.4% | 38% | 56% | 20% | 0.1 | 7.8% | -5% | +30% | -16% | -50% | -55% | 46% | 66 |
| 一心堂 002727 | 现金流红利 | 医药商业 | 24.4 | 15.3 | 0.96 | 0.89 | 3.5% | 88% | 33% | 7% | 1.3 | 25.6% | -0% | +3% | -11% | -24% | -36% | 30% | 66 |
| 百克生物 688276 | 亏损或困境 | 生物制品 | — | — | — | 1.74 | — | 21% | 87% | 50% | — | -1.9% | -17% | -24% | -15% | -37% | -46% | 36% | 66 |
| 康华生物 300841 | 定价权·品牌 | 生物制品 | 26.9 | 24.5 | 1.44 | 1.83 | 1.0% | 33% | 94% | 20% | — | 6.4% | -7% | +35% | -29% | -40% | -49% | 47% | 66 |
| 浩欧博 688656 | 中性 | 医疗器械 | 239.5 | — | — | 7.98 | 0.2% | 54% | 63% | 71% | 0.3 | 0.8% | +8% | +62% | -32% | -16% | -63% | 55% | 66 |
| 尔康制药 300267 | 亏损或困境 | 化学制药 | — | — | — | 1.66 | — | — | 23% | 43% | 4.9 | -2.0% | -15% | +23% | -5% | -21% | -40% | 50% | 67 |
| 艾德生物 300685 | 定价权·品牌 | 医疗器械 | 19.8 | 16.2 | 1.01 | 3.53 | 2.6% | 47% | 84% | 8% | 0.4 | 4.9% | +12% | -9% | -14% | -30% | -36% | 37% | 67 |
| 华纳药厂 688799 | 中性 | 化学制药 | 28.8 | 37.2 | 2.33 | 3.15 | 0.4% | 34% | 65% | 36% | 3.2 | -3.3% | +5% | +62% | +5% | -0% | -38% | 57% | 67 |
| 麦克奥迪 300341 | 中性 | 医疗器械 | 35.1 | — | — | 3.35 | 0.5% | 21% | 43% | 17% | 0.1 | 0.6% | -5% | -6% | -20% | -28% | -42% | 38% | 67 |
| 广誉远 600771 | 亏损或困境 | 中药Ⅱ | 94.9 | 57.2 | 1.73 | 4.03 | — | — | 68% | 22% | 0.3 | 3.4% | +7% | -5% | -24% | -36% | -40% | 26% | 67 |
| 东北制药 000597 | 中性 | 化学制药 | 31.8 | — | — | 1.23 | 1.2% | 34% | 39% | 25% | 2.4 | 12.4% | -7% | +1% | -8% | -17% | -28% | 28% | 68 |
| 理邦仪器 300206 | 中性 | 医疗器械 | 19.4 | — | — | 3.09 | 2.6% | 59% | 57% | 24% | 0.1 | 5.0% | +5% | +17% | -6% | -8% | -28% | 40% | 68 |
| 超研股份 301602 | 纯久期 | 医疗器械 | 63.7 | — | — | 5.18 | 0.9% | 34% | 69% | 8% | — | 1.4% | +6% | — | -25% | -43% | -50% | 38% | 69 |
| 南京医药 600713 | 中性 | 医药商业 | 11.0 | — | — | 0.95 | 3.2% | 39% | 6% | 5% | 8.8 | -18.3% | +3% | +14% | -1% | +2% | -25% | 29% | 69 |
| 赛诺医疗 688108 | 亏损或困境 | 医疗器械 | 82.3 | 81.7 | 2.40 | 6.92 | — | — | 63% | 6% | 0.8 | 2.5% | +40% | +97% | -14% | -51% | -59% | 62% | 69 |
| 九强生物 300406 | 成长兑现 | 医疗器械 | 30.7 | 16.9 | 0.77 | 2.01 | 8.9% | 44% | 75% | 10% | 2.0 | 7.8% | -4% | +5% | -4% | -14% | -26% | 29% | 69 |
| 葵花药业 002737 | 亏损或困境 | 中药Ⅱ | — | — | — | 1.76 | 1.7% | 69% | 56% | 22% | — | 1.8% | -23% | -26% | -19% | -27% | -32% | 26% | 69 |
| 昊海生科 688366 | 现金流红利 | 医疗器械 | 45.3 | 20.9 | 1.31 | 1.30 | 3.3% | 111% | 70% | 25% | 1.0 | 1.2% | +5% | -27% | -30% | -47% | -49% | 29% | 69 |
| 天智航 688277 | 亏损或困境 | 医疗器械 | — | — | — | 5.79 | — | — | 69% | 26% | — | -2.3% | +21% | +52% | -2% | -26% | -47% | 60% | 69 |
| 健信超导 688805 | 纯久期 | 医疗器械 | 75.1 | 88.1 | 3.83 | 5.68 | 0.7% | 50% | 26% | 10% | 0.0 | -0.6% | +17% | — | -1% | — | -40% | 63% | 69 |
| 中恒集团 600252 | 亏损或困境 | 中药Ⅱ | — | — | — | 1.35 | — | 41% | 59% | 13% | — | 0.6% | -14% | +11% | -19% | -23% | -42% | 34% | 71 |
| 中红医疗 300981 | 亏损或困境 | 医疗器械 | 174.7 | — | — | 1.35 | 2.1% | — | 12% | 23% | 4.7 | 0.7% | +15% | +10% | +35% | +4% | -42% | 56% | 71 |
| 康缘药业 600557 | 中性 | 中药Ⅱ | 23.0 | 20.3 | 1.69 | 1.43 | — | 80% | 72% | 45% | 0.0 | -0.8% | -9% | +4% | -11% | -34% | -42% | 31% | 71 |
| 德展健康 000813 | 亏损或困境 | 化学制药 | — | — | — | 1.57 | — | — | 59% | 20% | — | -4.5% | -11% | +23% | -11% | -15% | -39% | 44% | 72 |
| 百奥泰 688177 | 亏损或困境 | 生物制品 | — | — | — | 58.40 | — | — | 73% | 44% | — | -2.3% | +27% | +19% | -24% | -46% | -54% | 40% | 72 |
| 桂林三金 002275 | 现金流红利 | 中药Ⅱ | 17.8 | 15.8 | 1.58 | 2.22 | 4.0% | 68% | 73% | 26% | 0.5 | 6.4% | +1% | -3% | -10% | -18% | -20% | 21% | 73 |
| 五洲医疗 301234 | 中性 | 医疗器械 | 306.5 | — | — | 9.54 | 0.2% | 51% | 21% | 33% | 0.0 | 0.3% | -6% | +72% | +153% | +148% | -32% | 71% | 73 |
| 宏源药业 301246 | 重资产陷阱 | 化学制药 | 25.9 | 9.4 | 0.14 | 1.58 | 0.3% | 22% | 19% | 39% | 1.2 | -3.0% | -2% | +86% | -27% | +17% | -48% | 62% | 73 |
| 博雅生物 300294 | 亏损或困境 | 生物制品 | — | 23.8 | 1.59 | 0.98 | 1.5% | 64% | 55% | 19% | 0.3 | -8.5% | -9% | -25% | -36% | -47% | -48% | 27% | 73 |
| 新里程 002219 | 中性 | 医疗服务 | 240.8 | 91.3 | 2.12 | 3.72 | — | — | 30% | 42% | 4.2 | 0.4% | -1% | -19% | +0% | -7% | -37% | 44% | 74 |
| 亚虹医药 688176 | 亏损或困境 | 化学制药 | — | — | — | 5.49 | — | — | 76% | 1% | — | -7.8% | +2098% | +70% | +13% | +3% | -48% | 59% | 74 |
| 盈康生命 300143 | 亏损或困境 | 医疗服务 | 101.1 | 42.8 | 3.06 | 3.14 | 0.2% | 28% | 26% | 16% | 2.3 | 3.9% | +18% | +7% | +2% | -6% | -36% | 48% | 75 |
| 汇宇制药 688553 | 成长兑现 | 化学制药 | 66.1 | 1198.0 | 1.06 | 2.01 | 1.1% | 95% | 86% | 28% | 3.5 | 1.8% | -13% | +21% | +1% | -35% | -46% | 56% | 75 |
| 天宇股份 300702 | 中性 | 化学制药 | 83.1 | 24.5 | 0.72 | 2.11 | 0.2% | 31% | 37% | 43% | 3.1 | 7.7% | +5% | +42% | -8% | -21% | -36% | 38% | 75 |
| 仁和药业 000650 | 中性 | 中药Ⅱ | 19.1 | — | — | 1.16 | 2.8% | 49% | 37% | 16% | 0.0 | 9.3% | -12% | +1% | -2% | -17% | -26% | 24% | 75 |
| 达安基因 002030 | 亏损或困境 | 医疗器械 | — | — | — | 1.08 | — | 20% | 50% | 18% | 1.9 | 2.8% | -60% | +5% | -9% | -24% | -37% | 42% | 76 |
| 爱博医疗 688050 | 中性 | 医疗器械 | 32.0 | 19.0 | 1.00 | 2.64 | 0.8% | 34% | 76% | 30% | 2.2 | 2.8% | +37% | -33% | -35% | -50% | -56% | 31% | 76 |
| 太极集团 600129 | 中性 | 中药Ⅱ | 109.3 | 24.4 | 0.49 | 2.12 | — | 20% | 42% | 37% | 6.6 | -2.5% | -9% | -27% | -24% | -42% | -50% | 38% | 76 |
| 九芝堂 000989 | 现金流红利 | 中药Ⅱ | 23.2 | 25.2 | 1.26 | 2.08 | 3.3% | 115% | 59% | 22% | 0.1 | 8.1% | -10% | +14% | +6% | -28% | -37% | 34% | 76 |
| 万东医疗 600055 | 亏损或困境 | 医疗器械 | — | — | — | 1.76 | — | 54% | 42% | 6% | — | -3.1% | +6% | +4% | -30% | -39% | -46% | 30% | 76 |
| 新华医疗 600587 | 中性 | 医疗器械 | 18.0 | 12.0 | 1.20 | 0.97 | 2.8% | 35% | 26% | 21% | 1.2 | 7.2% | +2% | -11% | -11% | -24% | -32% | 26% | 77 |
| 奥浦迈 688293 | 纯久期 | 生物制品 | 60.6 | 49.0 | 1.29 | 2.47 | 0.7% | 143% | 59% | 9% | 1.5 | 1.3% | +6% | +36% | +12% | -6% | -48% | 61% | 78 |
| 福元医药 601089 | 中性 | 化学制药 | 20.2 | — | — | 2.09 | 3.0% | 49% | 67% | 35% | 0.0 | 3.2% | +3% | +57% | -31% | -37% | -48% | 46% | 78 |
| 英诺特 688253 | 纯久期 | 医疗器械 | 154.8 | — | — | 3.85 | 0.8% | 31% | 77% | 5% | 0.1 | 0.3% | -2% | -16% | +92% | +75% | -24% | 54% | 78 |
| 万孚生物 300482 | 亏损或困境 | 医疗器械 | — | 20.0 | 1.11 | 1.47 | 1.3% | 35% | 58% | 20% | 5.2 | 8.7% | -28% | -10% | -14% | -27% | -38% | 44% | 78 |
| 苑东生物 688513 | 中性 | 化学制药 | 28.3 | 26.8 | 2.44 | 2.68 | 1.1% | 32% | 80% | 32% | 0.4 | 2.3% | +4% | +109% | -27% | -37% | -48% | 60% | 79 |
| 爱迪特 301580 | 中性 | 医疗器械 | 37.8 | 28.3 | 0.59 | 3.60 | 0.6% | 27% | 49% | 8% | 0.0 | 1.7% | +20% | +8% | +69% | +49% | -45% | 72% | 79 |
| 阳光诺和 688621 | 纯久期 | 医疗服务 | 159.4 | 33.7 | 2.25 | 6.59 | 0.3% | 10% | 54% | 6% | 4.0 | -1.1% | +22% | +66% | +14% | -12% | -42% | 52% | 79 |
| 鲁抗医药 600789 | 中性 | 化学制药 | 55.2 | — | — | 1.51 | 0.7% | 32% | 23% | 39% | 3.3 | 4.8% | +1% | -4% | -16% | -27% | -37% | 30% | 79 |
| 奥锐特 605116 | 中性 | 化学制药 | 21.4 | 16.9 | 0.89 | 3.00 | 1.7% | 31% | 56% | 44% | 1.5 | 0.3% | +19% | +21% | -20% | -17% | -47% | 42% | 80 |
| 花园生物 300401 | 中性 | 化学制药 | 29.2 | — | — | 2.42 | 0.8% | 20% | 60% | 51% | 3.4 | 1.3% | -4% | +4% | -2% | -6% | -47% | 58% | 80 |
| 华北制药 600812 | 中性 | 化学制药 | 65.2 | — | — | 1.46 | 0.7% | 187% | 32% | 31% | 7.2 | 8.4% | -4% | +8% | -15% | -28% | -36% | 27% | 80 |
| 创新医疗 002173 | 重资产陷阱 | 医疗服务 | — | — | — | 4.92 | — | — | 7% | 58% | — | -0.7% | +3% | +170% | -14% | -23% | -57% | 66% | 81 |
| 复旦张江 688505 | 亏损或困境 | 化学制药 | — | — | — | 3.83 | — | 94% | 92% | 18% | — | 1.7% | -13% | +9% | -4% | -23% | -34% | 31% | 82 |
| 上海谊众 688091 | 纯久期 | 化学制药 | 121.8 | — | — | 5.62 | — | 30% | 93% | 18% | 0.4 | -0.3% | +10% | +18% | -14% | -44% | -51% | 59% | 84 |
| 千红制药 002550 | 中性 | 化学制药 | 28.6 | 20.5 | 0.89 | 3.07 | 2.3% | 47% | 44% | 22% | 0.1 | 2.8% | -12% | +30% | -15% | -40% | -45% | 34% | 84 |
| 成大生物 688739 | 纯久期 | 生物制品 | 199.0 | — | — | 0.91 | 0.5% | 71% | 84% | 19% | 0.0 | 0.8% | -8% | +3% | -20% | -30% | -35% | 21% | 85 |
| 智翔金泰 688443 | 亏损或困境 | 生物制品 | — | — | — | 6.65 | — | — | 50% | 17% | — | -8.1% | +686% | +9% | -15% | -33% | -44% | 44% | 85 |
| 开立医疗 300633 | 中性 | 医疗器械 | 52.3 | 27.9 | 0.82 | 2.85 | 0.9% | 30% | 67% | 27% | 1.1 | -0.4% | +9% | -10% | -23% | -40% | -51% | 35% | 86 |
| 仙琚制药 002332 | 现金流红利 | 化学制药 | 22.2 | 18.1 | 1.21 | 1.44 | 3.5% | 67% | 58% | 39% | 0.2 | 5.3% | -5% | -6% | -2% | -22% | -28% | 20% | 86 |
| 微电生理 688351 | 纯久期 | 医疗器械 | 148.2 | 131.6 | 3.21 | 4.78 | 0.1% | 19% | 64% | 9% | 0.1 | -0.3% | +21% | +22% | -20% | -29% | -36% | 43% | 87 |
| 中源协和 600645 | 纯久期 | 医疗器械 | 74.4 | — | — | 2.33 | — | — | 69% | 10% | 0.2 | 3.2% | -2% | +31% | -26% | -34% | -49% | 44% | 87 |
| 热景生物 688068 | 亏损或困境 | 医疗器械 | — | — | — | 3.58 | — | 64% | 57% | 29% | — | -3.5% | -52% | +162% | -42% | -62% | -68% | 73% | 87 |
| 海翔药业 002099 | 亏损或困境 | 化学制药 | — | — | — | 1.83 | — | — | 27% | 39% | 8.4 | -1.0% | -12% | +21% | -13% | -10% | -44% | 47% | 88 |
| 建发致新 301584 | 中性 | 医药商业 | 31.2 | — | — | 4.04 | 1.0% | 28% | 8% | 1% | 5.1 | 10.4% | +18% | — | -28% | — | -49% | 62% | 88 |
| 誉衡药业 002437 | 中性 | 化学制药 | 21.9 | — | — | 3.56 | — | — | 58% | 29% | 0.2 | 3.2% | -12% | +23% | +28% | +9% | -38% | 52% | 88 |
| 华邦健康 002004 | 现金流红利 | 化学制药 | 13.7 | — | — | 0.87 | 10.1% | 134% | 38% | 30% | 2.9 | 18.2% | -4% | +11% | -2% | -1% | -30% | 31% | 88 |
| 三诺生物 300298 | 成长兑现 | 医疗器械 | 66.9 | 22.7 | 0.99 | 3.01 | — | 38% | 55% | 30% | 2.0 | 4.8% | +18% | -33% | -6% | -25% | -36% | 25% | 89 |
| 威高骨科 688161 | 中性 | 医疗器械 | 34.6 | 27.8 | 1.39 | 2.14 | 1.5% | 52% | 66% | 8% | 0.1 | 3.7% | -6% | +12% | -19% | -29% | -44% | 37% | 90 |
| 国际医学 000516 | 重资产陷阱 | 医疗服务 | — | — | — | 2.79 | — | — | 8% | 79% | 7.7 | 11.3% | +14% | -19% | -6% | -26% | -38% | 38% | 91 |
| ST诺泰 688076 | 中性 | 化学制药 | 38.4 | — | — | 2.95 | 1.2% | 53% | 61% | 43% | 3.3 | -4.2% | +44% | +3% | -23% | -33% | -40% | 31% | 91 |
| 重药控股 000950 | 中性 | 医药商业 | 25.4 | 20.9 | 3.48 | 0.78 | 1.1% | 27% | 8% | 3% | 19.6 | -10.2% | +7% | +9% | -8% | -1% | -31% | 43% | 91 |
| 新华制药 000756 | 中性 | 化学制药 | 42.7 | — | — | 1.74 | 1.1% | 36% | 27% | 44% | 1.5 | 4.2% | +5% | -0% | -14% | -20% | -34% | 37% | 92 |
| 圣湘生物 688289 | 纯久期 | 医疗器械 | 68.4 | 35.8 | 1.70 | 1.31 | 3.3% | 112% | 72% | 13% | 5.5 | -0.6% | -37% | -15% | -14% | -27% | -36% | 35% | 92 |
| 力诺药包 301188 | 中性 | 医疗器械 | 310.7 | 72.5 | 2.42 | 4.75 | 0.3% | 36% | 21% | 37% | 1.8 | -4.8% | +6% | +18% | +98% | +78% | -56% | 76% | 93 |
| 美诺华 603538 | 中性 | 化学制药 | 79.5 | 62.1 | 2.07 | 3.17 | 0.4% | 32% | 35% | 38% | 2.3 | 0.6% | +1% | +53% | +100% | +41% | -53% | 71% | 93 |
| 佐力药业 300181 | 中性 | 中药Ⅱ | 14.9 | 12.1 | 0.50 | 2.84 | 2.6% | 82% | 68% | 28% | 0.9 | 1.5% | +19% | +10% | -15% | -31% | -34% | 31% | 94 |
| 佰仁医疗 688198 | 中性 | 医疗器械 | 58.6 | 39.5 | 0.86 | 7.76 | 1.1% | 75% | 89% | 33% | 0.3 | 0.1% | +28% | -1% | -34% | -41% | -46% | 41% | 97 |
| 海尔生物 688139 | 中性 | 医疗器械 | 38.2 | 34.0 | 2.43 | 2.20 | 1.1% | 40% | 48% | 16% | 0.3 | 3.0% | -7% | -9% | -2% | -12% | -33% | 33% | 97 |
| 海泰新光 688677 | 中性 | 医疗器械 | 56.8 | 45.3 | 1.56 | 7.32 | 0.7% | 46% | 64% | 30% | 0.7 | 1.1% | +8% | +17% | +92% | +81% | -62% | 77% | 98 |
| 派林生物 000403 | 中性 | 生物制品 | 36.7 | 23.0 | 2.88 | 1.22 | — | 44% | 49% | 21% | 2.1 | -3.4% | +3% | -14% | -24% | -43% | -52% | 33% | 98 |
| 富祥股份 300497 | 重资产陷阱 | 化学制药 | 76.4 | 15.2 | 0.69 | 4.17 | 0.3% | — | 17% | 48% | 4.2 | -0.4% | -10% | +82% | +21% | +68% | -34% | 66% | 98 |
| 欧普康视 300595 | 定价权·品牌 | 医疗器械 | 21.4 | 19.4 | 1.76 | 1.96 | 1.7% | 35% | 75% | 7% | 0.3 | 5.7% | +7% | -22% | -24% | -42% | -45% | 29% | 99 |
| 红日药业 300026 | 中性 | 中药Ⅱ | 552.2 | — | — | 1.16 | 0.3% | 100% | 58% | 26% | 0.7 | 6.9% | -9% | -6% | -6% | -23% | -32% | 28% | 99 |
| 马应龙 600993 | 轻资产现金牛 | 中药Ⅱ | 16.5 | 14.9 | 1.15 | 2.24 | 3.0% | 50% | 42% | 11% | 0.1 | 6.4% | +3% | +10% | -16% | -17% | -29% | 23% | 99 |
| 药石科技 300725 | 中性 | 医疗服务 | 47.4 | 41.3 | 1.21 | 2.19 | 0.9% | 31% | 42% | 32% | 0.3 | 1.4% | +7% | +16% | +12% | -8% | -34% | 48% | 100 |
| 泰恩康 301263 | 中性 | 化学制药 | — | 67.6 | 0.41 | 6.07 | 0.2% | 77% | 57% | 23% | 14.8 | -0.4% | -5% | +96% | -19% | -34% | -44% | 46% | 100 |
| 诺唯赞 688105 | 亏损或困境 | 生物制品 | — | 78.0 | 1.59 | 2.79 | 2.0% | — | 70% | 9% | 5.3 | 2.1% | -27% | -9% | +30% | -0% | -32% | 54% | 101 |
| 老百姓 603883 | 现金流红利 | 医药商业 | 23.7 | 18.0 | 1.29 | 1.46 | 3.0% | 60% | 32% | 7% | 1.4 | 26.8% | +3% | -8% | -7% | -26% | -41% | 28% | 102 |
| 海欣股份 600851 | 中性 | 化学制药 | 51.9 | — | — | 2.04 | 0.6% | 34% | 47% | 8% | 1.7 | -0.9% | -19% | +19% | +25% | +16% | -26% | 45% | 103 |
| 华兰疫苗 301207 | 现金流红利 | 生物制品 | 51.8 | 47.6 | 2.51 | 1.96 | 8.1% | 58% | 88% | 14% | — | 3.9% | -13% | +12% | -4% | -3% | -37% | 60% | 103 |
| 必贝特 688759 | 亏损或困境 | 化学制药 | — | — | — | 6.54 | — | — | 42% | 4% | — | -1.5% | — | — | -20% | — | -62% | 77% | 104 |
| 东诚药业 002675 | 中性 | 化学制药 | 52.3 | 39.5 | 1.52 | 2.39 | 0.6% | 36% | 45% | 27% | 2.1 | -0.0% | -8% | +13% | -7% | -27% | -30% | 30% | 105 |
| 泰诺麦博 688806 | 亏损或困境 | 生物制品 | — | — | — | 206.60 | — | — | 36% | 14% | — | -4.8% | — | — | — | — | -49% | 112% | 106 |
| 博腾股份 300363 | 亏损或困境 | 医疗服务 | — | 210.8 | 0.35 | 2.16 | 0.5% | 75% | 41% | 37% | 1.9 | 6.6% | -21% | +48% | -15% | -20% | -55% | 62% | 107 |
| 三博脑科 301293 | 中性 | 医疗服务 | 226.4 | 144.2 | 2.36 | 4.50 | — | 23% | 23% | 48% | 2.4 | -1.9% | +17% | +37% | -12% | -16% | -52% | 60% | 107 |
| 心脉医疗 688016 | 定价权·品牌 | 医疗器械 | 18.8 | 16.9 | 1.21 | 2.52 | 2.6% | 77% | 75% | 17% | 0.0 | 2.7% | +15% | -15% | -4% | -26% | -26% | 32% | 107 |
| 东富龙 300171 | 中性 | 医疗器械 | 41.0 | — | — | 1.35 | 0.8% | 30% | 35% | 16% | 0.2 | 3.6% | -2% | +19% | -10% | -8% | -41% | 39% | 107 |
| 奥赛康 002755 | 亏损或困境 | 化学制药 | 55.1 | 28.2 | 0.76 | 3.37 | 1.0% | 59% | 81% | 9% | 0.0 | 1.2% | -2% | +30% | -28% | -54% | -54% | 46% | 109 |
| 京新药业 002020 | 中性 | 化学制药 | 15.1 | 13.4 | 0.84 | 1.82 | 2.6% | 42% | 51% | 27% | 0.2 | 6.0% | +2% | +54% | -32% | -35% | -45% | 43% | 109 |
| 赛分科技 688758 | 中性 | 化学制药 | 59.9 | 60.3 | 1.63 | 7.92 | 0.4% | 24% | 71% | 14% | 0.6 | 1.0% | +24% | — | +50% | +28% | -29% | 52% | 110 |
| 石药景峰 000908 | 亏损或困境 | 化学制药 | — | — | — | 5.26 | — | — | 63% | 13% | 1.6 | -1.1% | -23% | +47% | +74% | +118% | -37% | 68% | 110 |
| 迪安诊断 300244 | 成长兑现 | 医疗服务 | 41.8 | 24.5 | 1.07 | 1.71 | 1.9% | 249% | 31% | 8% | 1.6 | 15.8% | -21% | +44% | +15% | +9% | -46% | 64% | 111 |
| 羚锐制药 600285 | 定价权·品牌 | 中药Ⅱ | 14.3 | 13.2 | 1.10 | 3.44 | 5.6% | 79% | 74% | 12% | 0.4 | 7.8% | +9% | -3% | +0% | -13% | -17% | 23% | 111 |
| 康恩贝 600572 | 现金流红利 | 中药Ⅱ | 22.4 | 18.3 | 0.87 | 1.58 | 3.4% | 79% | 58% | 27% | 0.1 | 8.7% | +3% | -1% | +2% | -3% | -19% | 26% | 111 |
| 微芯生物 688321 | 中性 | 化学制药 | 120.3 | 79.9 | 1.13 | 4.60 | 0.2% | 46% | 89% | 32% | 6.6 | -1.5% | +20% | +57% | -14% | -34% | -38% | 46% | 112 |
| 福瑞医科 300049 | 纯久期 | 医疗器械 | 67.2 | 45.5 | 1.34 | 5.68 | 0.4% | 26% | 74% | 14% | 0.5 | 2.0% | +16% | +124% | -40% | -33% | -58% | 60% | 112 |
| 义翘神州 301047 | 纯久期 | 生物制品 | 67.7 | 55.1 | 1.84 | 2.14 | 5.7% | 105% | 82% | 16% | 0.2 | 0.6% | +7% | +19% | +38% | +33% | -34% | 54% | 112 |
| 益诺思 688710 | 中性 | 医疗服务 | 471.2 | 85.2 | 0.83 | 4.75 | — | 25% | 38% | 21% | 1.1 | 1.9% | -2% | +26% | +80% | +89% | -31% | 72% | 112 |
| 益方生物 688382 | 亏损或困境 | 化学制药 | — | — | — | 8.01 | — | — | 92% | 0% | — | -2.2% | — | +105% | -28% | -54% | -63% | 69% | 113 |
| 舒泰神 300204 | 亏损或困境 | 化学制药 | — | — | — | 14.04 | — | — | 81% | 15% | — | -1.7% | -26% | +269% | -23% | -66% | -66% | 70% | 113 |
| 奇正藏药 002287 | 定价权·品牌 | 中药Ⅱ | 17.2 | — | — | 2.23 | 3.1% | 53% | 84% | 25% | 1.1 | 2.8% | +6% | +15% | -14% | -31% | -34% | 24% | 114 |
| 国药现代 600420 | 中性 | 化学制药 | 20.9 | 13.5 | 1.35 | 0.83 | 3.5% | 37% | 38% | 26% | 0.0 | 7.4% | -10% | -14% | -14% | -24% | -31% | 23% | 114 |
| 欧林生物 688319 | 亏损或困境 | 生物制品 | — | — | — | 13.16 | — | 88% | 94% | 29% | 3.9 | -0.3% | +9% | +139% | +11% | -14% | -54% | 71% | 114 |
| 我武生物 300357 | 定价权·品牌 | 生物制品 | 27.5 | 25.8 | 1.52 | 4.17 | 1.1% | 34% | 95% | 25% | 0.0 | 3.1% | +6% | +42% | -22% | -25% | -41% | 40% | 115 |
| 亿帆医药 002019 | 中性 | 化学制药 | 38.7 | 25.9 | 1.08 | 1.33 | 1.0% | 46% | 47% | 21% | 3.1 | 0.7% | +10% | +13% | -19% | -40% | -42% | 34% | 117 |
| 百洋医药 301015 | 中性 | 医药商业 | 22.5 | 19.5 | 1.62 | 5.25 | 2.5% | 61% | 30% | 10% | 4.1 | 2.5% | -0% | +1% | -0% | -7% | -38% | 41% | 120 |
| 国邦医药 605507 | 中性 | 化学制药 | 17.3 | 11.1 | 0.53 | 1.45 | 2.8% | 55% | 26% | 38% | 0.8 | 3.8% | +2% | +23% | -10% | -4% | -28% | 31% | 122 |
| 浙江医药 600216 | 中性 | 化学制药 | 15.1 | 11.0 | 1.10 | 1.05 | 2.2% | 31% | 35% | 38% | 0.5 | 8.4% | +3% | -11% | -7% | -21% | -39% | 34% | 122 |
| 可孚医疗 301087 | 成长兑现 | 医疗器械 | 30.1 | 25.0 | 1.04 | 2.21 | 3.4% | 98% | 44% | 22% | 1.3 | 3.6% | +4% | +34% | +19% | +34% | -28% | 42% | 122 |
| 迈威生物 688062 | 亏损或困境 | 化学制药 | — | — | — | 14.02 | — | — | 90% | 34% | — | -7.3% | +188% | +90% | -29% | -33% | -57% | 62% | 122 |
| 西藏药业 600211 | 定价权·品牌 | 生物制品 | 12.5 | 12.2 | 4.07 | 3.13 | 2.3% | 60% | 94% | 10% | 1.0 | 7.1% | +5% | +22% | -9% | -14% | -36% | 36% | 123 |
| 国药一致 000028 | 中性 | 医药商业 | 11.5 | 9.3 | 1.33 | 0.65 | 2.8% | 30% | 12% | 2% | 1.1 | -0.5% | -0% | -15% | -7% | -13% | -21% | 19% | 124 |
| 金域医学 603882 | 现金流红利 | 医疗服务 | 121.6 | 30.8 | 1.40 | 1.96 | 3.3% | 64% | 36% | 19% | 1.2 | 5.2% | -27% | +7% | -3% | -14% | -39% | 41% | 124 |
| 健帆生物 300529 | 现金流红利 | 医疗器械 | 23.7 | 19.3 | 1.93 | 3.72 | 3.2% | 75% | 81% | 36% | 1.5 | 3.4% | -7% | -32% | -19% | -34% | -37% | 27% | 124 |
| 美迪西 688202 | 亏损或困境 | 医疗服务 | — | 149.2 | 1.05 | 6.25 | — | — | 24% | 26% | 4.6 | 0.1% | -11% | +87% | +65% | +42% | -37% | 66% | 125 |
| 药康生物 688046 | 中性 | 医疗服务 | 69.0 | 63.1 | 2.34 | 5.56 | 0.7% | 71% | 68% | 21% | 0.8 | 1.8% | +15% | +21% | +102% | +65% | -34% | 63% | 126 |
| 成都先导 688222 | 中性 | 医疗服务 | 89.9 | 90.3 | 3.11 | 8.26 | 0.4% | 48% | 49% | 23% | 1.3 | 0.3% | +17% | +92% | +35% | +33% | -43% | 65% | 126 |
| 山东药玻 600529 | 中性 | 医疗器械 | 18.4 | 15.9 | 1.45 | 1.48 | 2.4% | 44% | 30% | 35% | 0.0 | 3.3% | +2% | -21% | -3% | -17% | -23% | 20% | 127 |
| 万泽股份 000534 | 中性 | 生物制品 | 62.6 | 40.3 | 0.90 | 6.79 | — | 23% | 75% | 43% | 5.7 | -2.5% | +18% | +72% | +13% | +46% | -53% | 72% | 127 |
| 华厦眼科 301267 | 轻资产现金牛 | 医疗服务 | 28.2 | 24.9 | 1.56 | 2.34 | 1.7% | 43% | 46% | 12% | 1.0 | 5.7% | +9% | -4% | -15% | -29% | -34% | 28% | 127 |
| 健友股份 603707 | 轻资产现金牛 | 化学制药 | 26.4 | 18.6 | 0.81 | 1.84 | 1.3% | 24% | 48% | 10% | 2.9 | 9.1% | +2% | -32% | -12% | -32% | -41% | 29% | 127 |
| 美好医疗 301363 | 中性 | 医疗器械 | 43.5 | 28.8 | 1.11 | 3.46 | 1.2% | 21% | 42% | 38% | 0.2 | 0.9% | +5% | +5% | -6% | -15% | -50% | 67% | 128 |
| 北芯生命 688712 | 亏损或困境 | 医疗器械 | 105.5 | — | — | 7.15 | — | — | 64% | 4% | 0.4 | 1.3% | +80% | — | — | — | -37% | 51% | 130 |
| 禾元生物 688765 | 亏损或困境 | 生物制品 | — | — | — | 4.60 | — | — | 61% | 46% | — | -5.9% | +53% | — | -47% | — | -74% | 64% | 131 |
| 威高血净 603014 | 中性 | 医疗器械 | 26.6 | 23.9 | 2.17 | 1.81 | 1.7% | 55% | 43% | 38% | 0.0 | 4.3% | +3% | — | -20% | -20% | -35% | 37% | 131 |
| 九洲药业 603456 | 中性 | 医疗服务 | 22.5 | 16.2 | 1.25 | 1.49 | 2.0% | 86% | 35% | 40% | 0.0 | 7.0% | +0% | +36% | -15% | -19% | -44% | 43% | 133 |
| 华兰股份 301093 | 中性 | 医疗器械 | 551.5 | 111.4 | 3.28 | 6.09 | 0.1% | 52% | 42% | 27% | 1.2 | -0.3% | +2% | +182% | +59% | +134% | -48% | 78% | 133 |
| 兴齐眼药 300573 | 成长兑现 | 化学制药 | 16.9 | 11.4 | 0.36 | 6.17 | 3.1% | 77% | 78% | 51% | 0.1 | 4.5% | +26% | +46% | -21% | -17% | -38% | 40% | 133 |
| 中国医药 600056 | 中性 | 医药商业 | 31.6 | — | — | 1.13 | 1.0% | 30% | 11% | 6% | 3.9 | 5.8% | -2% | -6% | -12% | -18% | -28% | 27% | 136 |
| 百普赛斯 301080 | 纯久期 | 生物制品 | 76.1 | 59.4 | 1.75 | 5.16 | 0.7% | 68% | 91% | 19% | 0.4 | 1.0% | +21% | +76% | +53% | +39% | -48% | 64% | 137 |
| 海正药业 600267 | 中性 | 化学制药 | 15.6 | — | — | 1.53 | 1.8% | 43% | 43% | 50% | 0.8 | 8.5% | -2% | +23% | +20% | +4% | -20% | 37% | 137 |
| 安科生物 300009 | 现金流红利 | 生物制品 | 19.8 | 16.8 | 1.20 | 3.26 | 3.0% | 57% | 78% | 31% | 0.1 | 4.9% | +4% | +14% | -11% | -28% | -36% | 39% | 139 |
| 康泰生物 300601 | 中性 | 生物制品 | 168.9 | 84.8 | 1.88 | 1.54 | 0.3% | 50% | 82% | 34% | 3.2 | 1.6% | -5% | -14% | -15% | -37% | -46% | 40% | 141 |
| 纳微科技 688690 | 中性 | 化学制药 | 68.0 | 59.1 | 1.56 | 6.85 | 0.3% | 30% | 78% | 25% | 0.1 | 1.2% | +9% | +48% | +37% | +22% | -30% | 57% | 143 |
| 海普瑞 002399 | 纯久期 | 化学制药 | 71.1 | — | — | 1.21 | 1.5% | 59% | 33% | 13% | 3.2 | 9.7% | -8% | +13% | -16% | -26% | -35% | 31% | 144 |
| 南微医学 688029 | 中性 | 医疗器械 | 28.6 | 24.2 | 1.34 | 3.49 | 1.9% | 51% | 64% | 19% | 0.3 | 3.1% | +17% | +24% | -3% | -14% | -33% | 40% | 146 |
| 华润江中 600750 | 定价权·品牌 | 中药Ⅱ | 17.0 | 15.3 | 1.39 | 3.76 | 5.9% | 96% | 65% | 29% | 0.0 | 5.0% | +3% | +8% | +5% | +12% | -19% | 28% | 149 |
| 广生堂 300436 | 亏损或困境 | 化学制药 | — | — | — | 72.02 | — | — | 62% | 38% | — | -0.8% | +3% | +173% | +1% | -41% | -42% | 75% | 151 |
| 博瑞医药 688166 | 中性 | 化学制药 | 157.5 | 158.1 | 0.41 | 4.97 | 0.0% | 20% | 56% | 42% | 7.9 | -0.1% | +6% | +63% | -29% | -68% | -73% | 69% | 152 |
| 华大基因 300676 | 亏损或困境 | 医疗服务 | — | 136.5 | 5.25 | 1.81 | — | 44% | 50% | 24% | 2.9 | -2.7% | -19% | +8% | -19% | -33% | -44% | 41% | 154 |
| 步长制药 603858 | 现金流红利 | 中药Ⅱ | 66.5 | — | — | 1.56 | 3.8% | 105% | 68% | 24% | 2.5 | 2.2% | -7% | +2% | -4% | -20% | -27% | 27% | 157 |
| 通化东宝 600867 | 现金流红利 | 生物制品 | 12.1 | 24.2 | 1.27 | 2.30 | 3.7% | 45% | 78% | 31% | 0.7 | 2.1% | +2% | +5% | +2% | -4% | -28% | 33% | 157 |
| 通策医疗 600763 | 中性 | 医疗服务 | 25.7 | 26.4 | 2.03 | 3.82 | — | 48% | 39% | 33% | 1.1 | 4.0% | +2% | -8% | -12% | -25% | -36% | 30% | 158 |
| 通化金马 000766 | 中性 | 化学制药 | 647.4 | — | — | 6.87 | — | — | 75% | 20% | 11.9 | 0.2% | -7% | +75% | -40% | -33% | -49% | 45% | 159 |
| 一品红 300723 | 亏损或困境 | 化学制药 | 72.9 | — | — | 8.71 | — | 50% | 81% | 38% | — | 0.4% | -26% | +97% | +6% | -49% | -60% | 65% | 161 |
| 神州细胞 688520 | 亏损或困境 | 生物制品 | — | — | — | — | — | — | 96% | 40% | — | -3.0% | +15% | +20% | -20% | -50% | -50% | 43% | 162 |
| 辽宁成大 600739 | 中性 | 生物制品 | 10.1 | — | — | 0.56 | 1.4% | 31% | 14% | 4% | — | 1.7% | -12% | +8% | -1% | -17% | -26% | 28% | 166 |
| 华润双鹤 600062 | 中性 | 化学制药 | 10.3 | 9.3 | 1.16 | 1.36 | 3.0% | 30% | 56% | 25% | 0.5 | 4.9% | +5% | -6% | -11% | -19% | -22% | 20% | 166 |
| 健康元 600380 | 中性 | 化学制药 | 14.0 | 11.8 | 1.97 | 1.10 | 2.4% | 27% | 63% | 18% | 1.2 | 20.2% | -4% | +4% | -19% | -28% | -32% | 26% | 168 |
| 康希诺 688185 | 亏损或困境 | 生物制品 | 419.0 | — | — | 3.42 | — | — | 70% | 37% | 4.2 | -1.1% | +1% | +3% | +10% | -22% | -44% | 56% | 170 |
| 大博医疗 002901 | 中性 | 医疗器械 | 24.1 | — | — | 4.85 | 1.4% | 58% | 70% | 22% | 0.4 | 4.1% | +22% | +57% | -12% | -29% | -33% | 34% | 171 |
| 美年健康 002044 | 轻资产现金牛 | 医疗服务 | 55.6 | 42.9 | 1.87 | 2.27 | 0.2% | 15% | 41% | 8% | 2.7 | 7.7% | +7% | +15% | -12% | -20% | -49% | 51% | 180 |
| 康弘药业 002773 | 现金流红利 | 生物制品 | 18.7 | 16.5 | 1.65 | 2.03 | 3.4% | 46% | 90% | 22% | 0.0 | 4.3% | +11% | +60% | -31% | -52% | -53% | 38% | 187 |
| 川宁生物 301301 | 中性 | 化学制药 | 31.7 | 20.8 | 1.30 | 2.35 | 2.1% | 51% | 29% | 49% | 1.0 | 4.4% | +6% | -13% | -16% | -33% | -35% | 31% | 187 |
| 安图生物 603658 | 现金流红利 | 医疗器械 | 19.0 | 16.7 | 1.19 | 2.17 | 4.0% | 70% | 65% | 31% | 0.0 | 3.4% | -2% | -17% | -3% | -20% | -30% | 23% | 188 |
| 皓元医药 688131 | 纯久期 | 医疗服务 | 73.1 | 55.5 | 1.35 | 5.88 | 0.3% | 20% | 48% | 18% | 3.5 | 1.0% | +28% | +104% | +24% | +42% | -32% | 60% | 189 |
| 康美药业 600518 | 中性 | 中药Ⅱ | 647.8 | — | — | 2.61 | — | — | 16% | 25% | 0.6 | 0.1% | +8% | -18% | -28% | -35% | -46% | 27% | 191 |
| 哈药股份 600664 | 中性 | 化学制药 | 38.3 | 32.4 | 1.91 | 3.21 | — | — | 26% | 15% | 1.3 | 1.8% | +5% | -16% | +126% | +98% | -34% | 51% | 196 |
| 翰宇药业 300199 | 亏损或困境 | 化学制药 | 157.7 | — | — | 23.71 | — | — | 58% | 52% | 5.1 | 0.1% | +11% | +39% | +28% | -21% | -41% | 55% | 202 |
| 国药股份 600511 | 中性 | 医药商业 | 10.6 | 9.9 | 1.65 | 1.08 | 3.0% | 30% | 8% | 1% | 0.3 | 3.9% | +5% | -14% | -3% | -9% | -14% | 15% | 204 |
| 贝达药业 300558 | 成长兑现 | 化学制药 | 44.3 | 36.1 | 1.09 | 3.13 | 0.3% | 20% | 84% | 28% | 2.0 | 1.3% | +15% | -13% | +5% | -33% | -46% | 56% | 207 |
| 沃森生物 300142 | 中性 | 生物制品 | 110.0 | — | — | 2.97 | 1.2% | 11% | 86% | 38% | 1.9 | 0.1% | -22% | -10% | +21% | -2% | -31% | 51% | 208 |
| 众生药业 002317 | 纯久期 | 中药Ⅱ | 105.1 | 73.3 | 3.67 | 5.23 | 0.8% | 62% | 59% | 15% | 0.3 | 2.3% | -2% | +60% | +31% | +7% | -37% | 57% | 209 |
| 常山药业 300255 | 亏损或困境 | 化学制药 | — | — | — | 17.95 | — | — | 22% | 40% | — | -1.1% | -28% | +211% | -63% | -56% | -69% | 69% | 213 |
| 大参林 603233 | 现金流红利 | 医药商业 | 15.7 | 14.5 | 1.04 | 2.84 | 4.4% | 76% | 36% | 14% | 1.3 | 14.6% | +9% | +23% | +10% | +15% | -29% | 32% | 214 |
| 振德医疗 603301 | 中性 | 医疗器械 | 77.4 | — | — | 3.78 | 0.4% | 45% | 35% | 41% | 1.9 | 0.2% | -11% | +234% | +16% | +238% | -35% | 53% | 214 |
| 乐普医疗 300003 | 中性 | 医疗器械 | 28.1 | 20.2 | 1.19 | 1.32 | 2.8% | 62% | 62% | 14% | 3.5 | 2.7% | -15% | +44% | -25% | -42% | -44% | 43% | 216 |
| 天士力 600535 | 中性 | 中药Ⅱ | 18.0 | 17.3 | 1.33 | 1.68 | 2.1% | 46% | 67% | 22% | 0.3 | 7.0% | -1% | +7% | -2% | -12% | -22% | 21% | 220 |
| 吉林敖东 000623 | 中性 | 中药Ⅱ | 7.0 | — | — | 0.69 | 2.7% | 38% | 49% | 6% | 18.9 | 1.0% | -7% | +17% | -4% | -8% | -25% | 28% | 221 |
| 恩华药业 002262 | 中性 | 化学制药 | 20.8 | 19.3 | 1.38 | 2.72 | 1.8% | 32% | 74% | 16% | 0.0 | 1.8% | +11% | +1% | -5% | -8% | -36% | 30% | 229 |
| 特宝生物 688278 | 中性 | 生物制品 | 21.5 | 18.5 | 0.69 | 7.49 | 1.1% | 30% | 93% | 22% | 0.5 | 1.7% | +34% | +15% | -31% | -33% | -38% | 34% | 233 |
| 济川药业 600566 | 定价权·品牌 | 中药Ⅱ | 12.9 | 13.1 | 1.64 | 1.72 | 6.7% | 76% | 82% | 14% | 0.7 | 3.4% | -12% | -3% | +5% | +4% | -18% | 29% | 237 |
| 丽珠集团 000513 | 现金流红利 | 化学制药 | 14.2 | 11.5 | 0.96 | 1.78 | 5.3% | 63% | 65% | 19% | 1.2 | 11.9% | -2% | -7% | -19% | -33% | -37% | 24% | 238 |
| 华兰生物 002007 | 中性 | 生物制品 | 29.5 | 24.2 | 2.42 | 2.17 | 7.7% | 37% | 66% | 20% | 0.3 | 3.5% | +1% | -6% | -11% | -20% | -28% | 22% | 238 |
| 华海药业 600521 | 中性 | 化学制药 | 38.1 | 27.0 | — | 2.51 | 0.6% | 35% | 60% | 44% | 4.2 | 0.2% | +1% | -4% | -5% | -29% | -48% | 40% | 239 |
| 华大智造 688114 | 亏损或困境 | 医疗器械 | — | — | — | 3.43 | — | — | 56% | 24% | 4.1 | 1.0% | -13% | +30% | -5% | -22% | -42% | 56% | 241 |
| 天坛生物 600161 | 中性 | 生物制品 | 32.1 | 22.7 | 1.62 | 2.03 | 1.6% | 22% | 49% | 34% | 0.1 | 0.9% | +13% | -19% | -25% | -40% | -44% | 23% | 243 |
| 九州通 600998 | 现金流红利 | 医药商业 | 12.7 | 11.4 | 1.14 | 0.94 | 3.9% | 46% | 8% | 7% | 4.3 | 8.9% | +5% | +4% | +3% | -4% | -17% | 21% | 255 |
| 鱼跃医疗 002223 | 定价权·品牌 | 医疗器械 | 23.0 | 16.7 | 1.04 | 1.94 | 4.6% | 44% | 50% | 11% | 0.0 | 5.4% | +4% | +7% | -31% | -29% | -45% | 30% | 259 |
| 普洛药业 000739 | 中性 | 化学制药 | 30.5 | 24.7 | 1.23 | 3.94 | 2.6% | 40% | 26% | 28% | 0.9 | 1.7% | -2% | +5% | +39% | +39% | -20% | 40% | 259 |
| 以岭药业 002603 | 现金流红利 | 中药Ⅱ | 19.3 | 17.6 | 1.10 | 2.43 | 5.0% | 70% | 64% | 48% | 0.0 | 7.0% | -14% | +9% | -4% | +2% | -29% | 34% | 265 |
| 迪哲医药 688192 | 亏损或困境 | 化学制药 | — | 12.4 | — | 23.49 | — | — | 96% | 12% | — | -2.6% | — | +39% | -1% | -31% | -55% | 60% | 265 |
| 达仁堂 600329 | 现金流红利 | 中药Ⅱ | 32.7 | 25.5 | 1.50 | 4.66 | 13.3% | 100% | 44% | 10% | 0.1 | 2.5% | -16% | +65% | -12% | -12% | -27% | 32% | 277 |
| 益丰药房 603939 | 现金流红利 | 医药商业 | 15.8 | 14.4 | 1.03 | 2.33 | 3.1% | 51% | 40% | 6% | 0.9 | 10.5% | +7% | -7% | +7% | -2% | -30% | 32% | 278 |
| 奕瑞科技 688301 | 中性 | 医疗器械 | 39.4 | 29.5 | 0.98 | 3.68 | 0.7% | 31% | 55% | 48% | 3.0 | -3.9% | +13% | +50% | +27% | +14% | -45% | 54% | 284 |
| 长春高新 000661 | 亏损或困境 | 生物制品 | — | 26.8 | 1.28 | 1.34 | 0.2% | 40% | 86% | 33% | 1.8 | -2.1% | -2% | -4% | -20% | -30% | -54% | 40% | 301 |
| ST人福 600079 | 中性 | 化学制药 | 15.1 | — | — | 1.58 | 2.6% | 42% | 45% | 24% | 1.6 | 6.7% | +2% | -22% | +6% | -8% | -30% | 25% | 306 |
| 东阿阿胶 000423 | 现金流红利 | 中药Ⅱ | 17.4 | 15.8 | 1.13 | 3.06 | 5.7% | 100% | 70% | 15% | 0.0 | 3.6% | +18% | -19% | +5% | +0% | -23% | 24% | 311 |
| 泽璟制药 688266 | 亏损或困境 | 化学制药 | 56.8 | 58.7 | — | 18.15 | — | — | 92% | 14% | 1.4 | 2.1% | +39% | +49% | +27% | +6% | -37% | 63% | 312 |
| 九安医疗 002432 | 中性 | 医疗器械 | 7.1 | — | — | 1.36 | 2.2% | 11% | 64% | 1% | — | -1.9% | -63% | -1% | +76% | +68% | -39% | 64% | 315 |
| 智飞生物 300122 | 亏损或困境 | 生物制品 | — | — | — | 2.11 | — | 24% | 27% | 20% | — | 15.8% | -38% | -28% | -30% | -45% | -52% | 45% | 317 |
| 昭衍新药 603127 | 中性 | 医疗服务 | 32.7 | 51.1 | — | 3.59 | 0.3% | 30% | 43% | 10% | 0.3 | 0.9% | -10% | +112% | +23% | +31% | -38% | 66% | 322 |
| 上海莱士 002252 | 中性 | 生物制品 | 26.8 | — | — | 1.00 | 1.0% | 20% | 41% | 7% | 2.4 | -3.5% | +4% | -12% | -22% | -30% | -40% | 20% | 324 |
| 白云山 600332 | 现金流红利 | 中药Ⅱ | 12.8 | 10.6 | 1.77 | 0.84 | 4.2% | 46% | 19% | 9% | 5.0 | 5.0% | +3% | -7% | -20% | -24% | -27% | 17% | 329 |
| 同仁堂 600085 | 轻资产现金牛 | 中药Ⅱ | 34.1 | 25.3 | 1.95 | 2.43 | 2.1% | 58% | 47% | 13% | 1.3 | 6.5% | +4% | -20% | -24% | -35% | -40% | 21% | 331 |
| 君实生物 688180 | 亏损或困境 | 生物制品 | — | — | — | 5.78 | — | — | 69% | 35% | — | -3.1% | +20% | +25% | -2% | -28% | -41% | 48% | 344 |
| 万泰生物 603392 | 亏损或困境 | 医疗器械 | — | — | — | 2.98 | — | 32% | 86% | 24% | — | -1.5% | -45% | -36% | -38% | -56% | -57% | 36% | 350 |
| 信立泰 002294 | 中性 | 化学制药 | 52.0 | 44.4 | 1.85 | 4.09 | 1.8% | 95% | 73% | 14% | 0.7 | 0.2% | +8% | +64% | -36% | -40% | -56% | 55% | 350 |
| 英科医疗 300677 | 中性 | 医疗器械 | 31.2 | 16.0 | 0.73 | 1.87 | 0.4% | 10% | 24% | 28% | 5.3 | 2.8% | +14% | +55% | +40% | +41% | -42% | 55% | 355 |
| 惠泰医疗 688617 | 中性 | 医疗器械 | 38.1 | 34.3 | 1.32 | 11.53 | 0.4% | 50% | 71% | 24% | 0.0 | 2.4% | +29% | -5% | +4% | -11% | -45% | 42% | 356 |
| 三生国健 688336 | 中性 | 生物制品 | 12.3 | 58.0 | 2.42 | 4.44 | 0.8% | 10% | 77% | 18% | — | 6.7% | +72% | +184% | +3% | +14% | -42% | 69% | 378 |
| 新产业 300832 | 定价权·品牌 | 医疗器械 | 23.6 | 21.8 | 1.28 | 4.51 | 2.3% | 56% | 71% | 18% | 0.0 | 4.1% | +14% | -20% | -6% | -13% | -43% | 34% | 405 |
| 华润三九 000999 | 定价权·品牌 | 中药Ⅱ | 12.6 | 11.4 | 1.04 | 1.81 | 4.2% | 50% | 54% | 19% | 0.7 | 9.0% | +20% | -15% | -11% | -17% | -26% | 21% | 414 |
| 甘李药业 603087 | 中性 | 生物制品 | 36.4 | 29.8 | 1.57 | 3.58 | 1.4% | 52% | 76% | 27% | 0.0 | -0.3% | +33% | +59% | +4% | -1% | -34% | 42% | 419 |
| 泰格医药 300347 | 纯久期 | 医疗服务 | 471.1 | 49.8 | 0.94 | 2.21 | 0.2% | 24% | 39% | 4% | 2.1 | 2.1% | -1% | +4% | -12% | -27% | -46% | 48% | 431 |
| 华东医药 000963 | 现金流红利 | 化学制药 | 13.9 | 12.8 | 1.60 | 1.89 | 3.4% | 46% | 32% | 13% | 0.4 | 5.8% | +5% | +18% | -30% | -40% | -41% | 32% | 480 |
| 艾力斯 688578 | 定价权·品牌 | 化学制药 | 18.6 | 17.4 | 1.16 | 5.88 | 1.1% | 21% | 96% | 5% | 0.0 | 5.1% | +87% | +78% | +7% | +20% | -32% | 48% | 497 |
| 百奥赛图 688796 | 亏损或困境 | 医疗服务 | 146.3 | 133.4 | 2.38 | 22.12 | — | — | 73% | 33% | 1.4 | 0.3% | +37% | — | +128% | — | -25% | 82% | 536 |
| 诺诚健华 688428 | 亏损或困境 | 化学制药 | 61.0 | 179.2 | — | 7.31 | — | — | 86% | 6% | 2.5 | 0.3% | +56% | +67% | +54% | +7% | -35% | 53% | 561 |
| 凯莱英 002821 | 中性 | 医疗服务 | 56.8 | 42.1 | 1.45 | 3.31 | 0.8% | 41% | 44% | 32% | 0.2 | -0.2% | -13% | +24% | +78% | +49% | -25% | 54% | 588 |
| 复星医药 600196 | 中性 | 化学制药 | 17.6 | 15.5 | 0.82 | 1.22 | 1.7% | 31% | 48% | 17% | 6.0 | 1.2% | -2% | +8% | -14% | -22% | -34% | 28% | 597 |
| 上海医药 601607 | 中性 | 医药商业 | 12.9 | 11.3 | 1.61 | 0.79 | 2.8% | 38% | 12% | 7% | 4.2 | 12.0% | +7% | -14% | -4% | -13% | -21% | 15% | 616 |
| 石药创新 300765 | 中性 | 化学制药 | 60.3 | — | — | 15.66 | — | 50% | 43% | 33% | 0.5 | 3.4% | -6% | +36% | +22% | -19% | -60% | 69% | 616 |
| 科伦药业 002422 | 中性 | 化学制药 | 36.5 | — | — | 2.71 | 1.4% | 47% | 52% | 30% | 1.4 | 3.4% | -1% | +0% | +45% | +9% | -29% | 47% | 667 |
| 荣昌生物 688331 | 亏损或困境 | 生物制品 | 12.0 | 18.0 | — | 8.44 | — | — | 80% | 29% | 0.1 | 6.2% | +62% | +158% | +60% | +51% | -36% | 70% | 701 |
| 片仔癀 600436 | 中性 | 中药Ⅱ | 41.3 | 34.7 | 2.04 | 5.11 | 2.4% | 83% | 46% | 10% | 0.5 | 1.0% | +1% | -20% | -26% | -41% | -49% | 29% | 747 |
| 康龙化成 300759 | 中性 | 医疗服务 | 44.2 | 37.6 | 1.39 | 4.63 | 0.5% | 21% | 36% | 41% | 1.9 | 0.0% | +11% | +12% | +46% | +30% | -40% | 48% | 757 |
| 爱尔眼科 300015 | 定价权·品牌 | 医疗服务 | 30.6 | 22.1 | 1.10 | 3.39 | 2.1% | 42% | 50% | 19% | 1.1 | 4.7% | +12% | -16% | -22% | -38% | -42% | 28% | 780 |
| 海思科 002653 | 纯久期 | 化学制药 | 83.2 | 78.3 | — | 16.39 | 1.1% | 116% | 71% | 10% | 1.6 | 1.2% | +13% | +57% | +37% | +18% | -31% | 52% | 789 |
| 联影医疗 688271 | 中性 | 医疗器械 | 50.6 | 39.1 | 1.56 | 4.06 | 0.3% | 13% | 48% | 19% | 0.7 | -0.1% | +14% | -0% | -13% | -20% | -38% | 34% | 895 |
| 云南白药 000538 | 现金流红利 | 中药Ⅱ | 17.4 | 16.4 | 2.05 | 2.22 | 5.1% | 90% | 27% | 8% | 0.1 | 4.7% | +4% | -2% | -8% | -8% | -18% | 14% | 910 |
| 百利天恒 688506 | 亏损或困境 | 化学制药 | — | — | — | 23.42 | — | — | 75% | 8% | — | -1.5% | +53% | +68% | -19% | -21% | -50% | 56% | 1080 |
| 迈瑞医疗 300760 | 定价权·品牌 | 医疗器械 | 26.2 | 23.9 | 1.71 | 5.08 | 2.5% | 65% | 64% | 18% | 0.0 | 4.4% | +3% | -24% | -10% | -30% | -45% | 28% | 2059 |
| 恒瑞医药 600276 | 中性 | 化学制药 | 39.5 | 32.9 | 1.94 | 4.74 | 0.4% | 20% | 86% | 12% | 0.0 | 1.8% | +14% | +30% | -22% | -30% | -37% | 34% | 3054 |
| 百济神州 688235 | 亏损或困境 | 化学制药 | 93.0 | — | — | 11.24 | — | — | 85% | 17% | 1.0 | 3.9% | +59% | +67% | +1% | +6% | -36% | 49% | 3982 |
| 药明康德 603259 | 成长兑现 | 医疗服务 | 21.3 | 20.8 | 0.95 | 5.55 | 1.4% | 60% | 41% | 24% | 0.6 | 2.8% | +5% | +73% | +74% | +58% | -23% | 45% | 4622 |
点表头排序。市值单位亿元;去年/YTD 为前复权涨幅;债/EBITDA = 有息负债 ÷ EBITDA。